Neoplastic Processes - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

RGD DISEASE ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.

Term:	Neoplastic Processes	go back to main search page
Accession:	DOID:9008192	browse the term
Definition:	The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity.
Synonyms:	primary_id:	MESH:D009385

show annotations for term's descendants Sort by:
Rat (740) Mouse (746) Human (791) Chinchilla (631) Bonobo (669) Dog (724) Squirrel (641) Pig (711) Green Monkey (659) Naked Mole-rat (623) All
Genes (669)

Neoplastic Processes

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apolipoprotein B mRNA editing enzyme catalytic subunit 3A

CTD Direct Evidence: marker/mechanism

NCBI chr22:19,866,522...19,872,836

G

apolipoprotein B mRNA editing enzyme catalytic subunit 3B

CTD Direct Evidence: marker/mechanism

NCBI chr22:19,892,548...19,902,455
Ensembl chr22:37,711,588...37,721,265

G

chromatin assembly factor 1 subunit B

protein:increased expression::

NCBI chr21:22,755,721...22,786,958
Ensembl chr21:36,113,971...36,143,575

G

ETS transcription factor ERG

CTD Direct Evidence: marker/mechanism

NCBI chr21:24,737,829...25,016,378
Ensembl chr21:38,087,339...38,281,403

G

ETS variant transcription factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:14,569,239...14,665,713
Ensembl chr 7:13,909,487...14,004,808

G

ETS variant transcription factor 4

CTD Direct Evidence: marker/mechanism

NCBI chr17:13,850,823...13,869,347
Ensembl chr17:14,099,160...14,116,186

G

ETS variant transcription factor 5

CTD Direct Evidence: marker/mechanism

NCBI chr 3:183,076,677...183,139,886
Ensembl chr 3:191,545,915...191,606,550

G

EWS RNA binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr22:10,323,622...10,356,039
Ensembl chr22:28,131,109...28,163,134

G

high density lipoprotein binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr2B:128,498,647...128,587,305
Ensembl chr2B:247,293,154...247,335,318

G

homeobox D9

CTD Direct Evidence: marker/mechanism

NCBI chr2B:63,401,813...63,404,731
Ensembl chr2B:181,112,002...181,113,415

G

HRas proto-oncogene, GTPase

CTD Direct Evidence: marker/mechanism

NCBI chr11:537,488...540,810
Ensembl chr11:568,305...571,078

Anaplasia

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carbonic anhydrase 9

CTD Direct Evidence: marker/mechanism

NCBI chr 9:35,525,877...35,533,159
Ensembl chr 9:36,328,303...36,335,340

G

hypoxia inducible factor 1 subunit alpha

CTD Direct Evidence: marker/mechanism

NCBI chr14:42,295,691...42,348,478
Ensembl chr14:60,552,374...60,604,885

Blast Crisis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activation induced cytidine deaminase

CTD Direct Evidence: marker/mechanism

NCBI chr12:8,688,392...8,699,008
Ensembl chr12:8,904,273...8,913,917

G

BCR activator of RhoGEF and GTPase

CTD Direct Evidence: marker/mechanism

G

estrogen receptor 2

NCBI chr14:44,807,875...44,919,780
Ensembl chr14:63,064,402...63,131,303

G

heme oxygenase 1

NCBI chr22:16,388,368...16,401,289
Ensembl chr22:34,230,825...34,244,063

G

transcobalamin 2

protein:increased expression::

NCBI chr22:11,635,107...11,655,137
Ensembl chr22:29,435,517...29,455,494

Bone Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 12-lipoxygenase, 12S type

associated with Prostatic Neoplasms;

NCBI chr17:7,026,839...7,041,598
Ensembl chr17:7,014,591...7,029,602

G

BRCA1 interacting DNA helicase 1

associated with Breast Neoplasms; human gene in a mouse model

NCBI chr17:55,786,568...55,973,366
Ensembl chr17:60,901,073...61,083,462

G

C-X-C motif chemokine receptor 4

disease_progression

associated with hepatocellular carcinoma;protein:increased expression:liver (human)

NCBI chr2B:23,744,271...23,748,106
Ensembl chr2B:140,181,829...140,189,647

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

associated with Breast Neoplasms;mRNA:increased expression:bone element (human)

NCBI chr 6:129,591,858...129,673,000
Ensembl chr 6:133,698,640...133,783,644

G

matrix metallopeptidase 13

associated with Carcinoma, Renal Cell; mRNA, protein:increased expression:bone (human)

NCBI chr11:97,890,811...97,902,778
Ensembl chr11:101,377,001...101,387,679

G

platelet derived growth factor D

associated with prostate carcinoma

NCBI chr11:98,852,652...99,110,147
Ensembl chr11:102,357,079...102,593,273

Carcinogenesis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 9:101,834,189...102,005,811
Ensembl chr 9:130,484,333...130,652,941

G

ADP-ribosylarginine hydrolase

NCBI chr 3:116,702,236...116,713,051
Ensembl chr 3:123,614,819...123,625,353

G

aldo-keto reductase family 1 member A1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:44,853,867...44,871,764
Ensembl chr 1:46,211,859...46,230,072

G

AKT serine/threonine kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:85,417,229...85,444,722
Ensembl chr14:105,208,128...105,236,756

G

B-Raf proto-oncogene, serine/threonine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 7:132,651,908...132,855,422
Ensembl chr 7:145,138,510...145,327,115

G

caveolin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:108,497,125...108,533,090
Ensembl chr 7:121,193,424...121,229,655

G

cyclin dependent kinase inhibitor 2A

CTD Direct Evidence: marker/mechanism

NCBI chr 9:21,803,862...21,831,322

G

cut like homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:93,954,599...94,432,697
Ensembl chr 7:107,191,124...107,609,940

G

DNA methyltransferase 1

disease_progression

NCBI chr19:9,681,847...9,745,334
Ensembl chr19:10,342,478...10,406,972

G

DNA methyltransferase 3 alpha

disease_progression

NCBI chr2A:25,229,593...25,344,733
Ensembl chr2A:25,331,095...25,412,605

G

endothelial PAS domain protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr2A:46,403,411...46,492,734
Ensembl chr2A:47,332,308...47,421,560

G

erb-b2 receptor tyrosine kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr17:17,560,337...17,600,808
Ensembl chr17:17,777,434...17,805,862

G

GATA binding protein 3

CTD Direct Evidence: marker/mechanism

NCBI chr10:8,075,951...8,105,573
Ensembl chr10:8,064,207...8,086,272

G

ISG15 ubiquitin like modifier

CTD Direct Evidence: marker/mechanism

Ensembl chr 1:927,418...928,491

G

KRAS proto-oncogene, GTPase

CTD Direct Evidence: marker/mechanism

PMID:26595770 PMID:29247004

NCBI chr12:61,062,689...61,108,524
Ensembl chr12:63,679,293...63,724,335

G

mitogen-activated protein kinase kinase kinase 8

PMID:15287022 PMID:23533274

RGD:151356924 RGD:151356978

NCBI chr10:30,579,220...30,607,249
Ensembl chr10:30,933,483...30,960,824

G

MET proto-oncogene, receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 7:108,646,278...108,772,238
Ensembl chr 7:121,365,438...121,468,159

G

NFE2 like bZIP transcription factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr2B:64,509,446...64,544,600
Ensembl chr2B:182,214,116...182,248,085

G

platelet activating factor acetylhydrolase 1b regulatory subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:2,584,349...2,676,928
Ensembl chr17:2,590,007...2,680,994

G

POU class 5 homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:30,910,421...30,916,465
Ensembl chr 6:31,775,343...31,781,426

G

secreted protein acidic and cysteine rich

CTD Direct Evidence: marker/mechanism

NCBI chr 5:147,087,903...147,112,466
Ensembl chr 5:153,090,181...153,115,750

G

TNF superfamily member 8

CTD Direct Evidence: marker/mechanism

NCBI chr 9:85,998,567...86,036,373
Ensembl chr 9:114,360,206...114,397,822

Circulating Neoplastic Cells

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

erb-b2 receptor tyrosine kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr17:17,560,337...17,600,808
Ensembl chr17:17,777,434...17,805,862

Liver Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

associated with colorectal cancer;mRNA:increased expression:liver (mouse)

NCBI chr17:57,556,294...57,577,294
Ensembl chr17:62,702,341...62,733,853

G

B-Raf proto-oncogene, serine/threonine kinase

severity

associated with colorectal cancer;DNA:missense mutation:cds:p.V600E (human)
associated with colorectal cancer;DNA:mutation:cds:
associated with colorectal cancer;DNA:mutations:multiple
associated with skin melanoma;DNA:missense mutations:cds:
associated with colorectal cancer;DNA:missense mutations:cds:pV599E,p.V600E (human)

PMID:22331825 PMID:23010994 PMID:26775732 PMID:27737491 PMID:28787433

RGD:11554843 RGD:14696791 RGD:15039394 RGD:18337264 RGD:18337265

NCBI chr 7:132,651,908...132,855,422
Ensembl chr 7:145,138,510...145,327,115

G

C-C motif chemokine ligand 2

disease_progression

associated with colorectal cancer

NCBI chr17:22,528,154...22,530,091
Ensembl chr17:22,820,890...22,823,384

G

C-C motif chemokine ligand 5

treatment

associated with Animal Mammary Neoplasms;

NCBI chr17:20,915,198...20,923,530
Ensembl chr17:21,210,798...21,219,172

G

cyclin D2

associated with colorectal cancer;protein:increased expression:colorectum

NCBI chr12:4,385,957...4,417,602
Ensembl chr12:4,309,272...4,335,551

G

cyclin G1

treatment

human cells in mouse model

NCBI chr 5:158,814,563...158,822,019
Ensembl chr 5:165,592,971...165,598,728

G

CD44 molecule (IN blood group)

associated with Breast Neoplasm;protein:increased expression:liver

NCBI chr11:35,110,732...35,258,238
Ensembl chr11:34,985,634...35,079,009

G

chromodomain helicase DNA binding protein 4

ameliorates

associated with human colon adenocarcinoma cells in a mouse model

NCBI chr12:6,701,004...6,738,621
Ensembl chr12:6,619,089...6,656,076

G

C-X-C motif chemokine ligand 10

treatment

associated with colon carcinoma;

NCBI chr 4:48,182,355...48,184,733
Ensembl chr 4:54,020,204...54,022,606

G

C-X-C motif chemokine ligand 12

ameliorates

associated with colorectal cancer; human cells in mouse model

NCBI chr10:41,296,975...41,384,864
Ensembl chr10:44,552,480...44,564,231

G

C-X-C motif chemokine ligand 8

associated with colorectal cancer; human colon adenocarcinoma cells in a mouse model

NCBI chr 4:50,452,857...50,456,015
Ensembl chr 4:56,286,708...56,288,083

G

C-X-C motif chemokine receptor 4

ameliorates

associated with colorectal cancer; human cells in mouse model
human cells in mouse model; associated with colorectal cancer

PMID:29436696 PMID:30789971

RGD:151893289 RGD:152023643

NCBI chr2B:23,744,271...23,748,106
Ensembl chr2B:140,181,829...140,189,647

G

death domain associated protein

exacerbates

associated with colon cancer; mRNA:decreased expression:liver (human)
associated with neuroendocrine tumor;DNA:mutations:CDS:multiple (human)
associated with pancreatic endocrine carcinoma;DNA:mutations:CDS:multiple (human)

PMID:30339629 PMID:30342802 PMID:31942198

RGD:152025194 RGD:152025199 RGD:152025203

NCBI chr 6:32,890,846...32,895,307
Ensembl chr 6:34,004,543...34,008,717

G

discoidin domain receptor tyrosine kinase 1

treatment

mRNA:increased expression:liver (mouse)
human cells in mouse model; nilotinib

PMID:29438985 PMID:30666650 PMID:33110221

RGD:151347537 RGD:151347685 RGD:151347840

NCBI chr 6:30,625,871...30,645,066
Ensembl chr 6:31,496,047...31,513,455

G

discoidin domain receptor tyrosine kinase 2

ameliorates

associated with colon carcinoma
associated with melanoma;

PMID:21701781 PMID:22071959

RGD:150429701 RGD:150429713

NCBI chr 1:138,048,730...138,200,426
Ensembl chr 1:141,932,158...141,990,766

G

dedicator of cytokinesis 6

ameliorates

associated with stomach cancer;

NCBI chr19:10,747,850...10,811,483
Ensembl chr19:11,459,062...11,513,220

G

F-box and WD repeat domain containing 7

disease_progression

associated with colorectal cancer;

NCBI chr 4:144,660,676...144,874,404
Ensembl chr 4:156,312,274...156,402,351

G

fibroblast growth factor receptor 1

associated with colorectal cancer;mRNA:increased expression:colorectal mucosa:

NCBI chr 8:37,713,133...37,773,098
Ensembl chr 8:34,890,147...34,948,904

G

FOS like 2, AP-1 transcription factor subunit

human cells in mouse model

NCBI chr2A:28,392,328...28,416,838
Ensembl chr2A:28,485,613...28,498,397

G

glypican 3

protein:increased expression:blood serum (human)

NCBI chr X:122,677,072...123,131,511
Ensembl chr X:132,979,612...133,432,441

G

hydroxymethylbilane synthase

associated with colon adenocarcinoma;protein:decreased activity:liver(rat)

NCBI chr11:113,923,004...113,931,732
Ensembl chr11:117,852,295...117,860,757

G

interleukin 2

treatment

associated with Colorectal Neoplasms, Carcinoma, Hepatocellular;
associated with colon carcinoma

PMID:9354462 PMID:11591892

RGD:14928215 RGD:8663446

NCBI chr 4:114,637,328...114,642,586
Ensembl chr 4:125,782,563...125,787,984

G

IQ motif and Sec7 domain ArfGEF 1

human cells in mouse model

NCBI chr 3:12,820,552...13,202,925
Ensembl chr 3:13,167,299...13,235,285

G

mitogen-activated protein kinase kinase 7

associated with colon cancer;protein:increased expression:colon (human)

NCBI chr19:7,205,124...7,215,776
Ensembl chr19:8,057,598...8,066,512

G

MPL proto-oncogene, thrombopoietin receptor

exacerbates
severity

associated with pancreatic cancer; protein:increased expression:liver, pancreas (human)
associated with pancreatic ductal adenocarcinoma; human cells in mouse model
associated with colorectal carcinoma;protein:increased expression:colorectum (human)

PMID:23747337 PMID:30770989

RGD:126925751 RGD:126925752

NCBI chr 1:42,639,191...42,654,738
Ensembl chr 1:44,018,395...44,034,492

G

NRAS proto-oncogene, GTPase

susceptibility

associated with melanoma;DNA:mutations: exons (human)
associated with colorectal cancer;DNA:mutations:exons (human)
human gene in a mouse model;DNA:missense mutations:cds:p.G12V, p.Q61K (human)

PMID:26799184 PMID:28011498 PMID:28787433

RGD:14696774 RGD:14696791 RGD:14696792

NCBI chr 1:87,837,146...87,850,013
Ensembl chr 1:122,890,505...122,903,585

G

protein tyrosine phosphatase receptor type B

treatment

mouse tumor cells in mouse recipient

NCBI chr12:68,025,973...68,147,613
Ensembl chr12:70,797,843...70,915,308

G

RPTOR independent companion of MTOR complex 2

disease_progression

mRNA:increased expression:liver (human)

NCBI chr 5:71,299,215...71,435,290
Ensembl chr 5:76,389,130...76,469,830

G

ring finger protein 43

associated with colorectal adenocarcinoma;mRNA:increased expression:liver (human)

NCBI chr17:52,420,516...52,492,813
Ensembl chr17:57,276,761...57,347,748

G

solute carrier family 3 member 2

severity

associated with colon adenocarcinoma

NCBI chr11:58,212,395...58,241,686
Ensembl chr11:61,565,680...61,594,579

G

solute carrier family 7 member 5

severity

associated with colon cancer
associated with colon adenocarcinoma

PMID:11718450 PMID:11745822

RGD:151361129 RGD:151361130

NCBI chr16:68,512,407...68,552,763

G

SMAD family member 4

treatment

associated with colorectal carcinoma; DNA:mutations: :
associated with colorectal carcinoma;protein:decreased expression:colorectum:

PMID:17390050 PMID:29551247

RGD:18937000 RGD:21066338

NCBI chr18:44,402,112...44,456,779
Ensembl chr18:47,764,568...47,797,359

G

SRY-box transcription factor 30

ameliorates

NCBI chr 5:153,022,109...153,067,734
Ensembl chr 5:159,640,126...159,737,776

G

SRC proto-oncogene, non-receptor tyrosine kinase

disease_progression

associated with colon cancer;protein:increased activity:colon

NCBI chr20:33,667,614...33,727,126
Ensembl chr20:34,822,271...34,839,634

G

vascular endothelial growth factor A

associated with colorectal carcinoma;mRNA,protein:increased expression:liver:

NCBI chr 6:43,361,053...43,377,366
Ensembl chr 6:44,650,365...44,666,353

lung metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase domain 28

ameliorates

associated with lung adenocarcinoma;
associated with lung carcinoma, breast carcinoma

PMID:22636800 PMID:26800504

RGD:11531771 RGD:153297785

NCBI chr 8:23,549,892...23,623,859
Ensembl chr 8:20,474,029...20,540,692

G

Rho GTPase activating protein 5

associated with Mammary Neoplasms, Experimental

NCBI chr14:12,844,042...12,934,411
Ensembl chr14:31,036,511...31,125,349

G

AT-rich interaction domain 2

exacerbates

associated with hepatocellular carcinoma,

NCBI chr12:42,823,236...43,004,465
Ensembl chr12:43,692,914...43,871,564

G

carbonic anhydrase 12

ameliorates

associated with breast cancer;

NCBI chr15:42,270,188...42,328,952
Ensembl chr15:60,565,592...60,624,008

G

Cbl proto-oncogene B

severity

associated with stomach carcinoma;

NCBI chr 3:102,752,406...102,966,414
Ensembl chr 3:109,690,120...109,905,191

G

cyclin G1

NCBI chr 5:158,814,563...158,822,019
Ensembl chr 5:165,592,971...165,598,728

G

chromodomain helicase DNA binding protein 4

ameliorates

associated with human colon adenocarcinoma cells in a mouse model

NCBI chr12:6,701,004...6,738,621
Ensembl chr12:6,619,089...6,656,076

G

collagen type X alpha 1 chain

ameliorates

associated with H1299 cell

NCBI chr 6:113,921,538...113,961,490
Ensembl chr 6:118,067,477...118,074,684

G

C-X-C motif chemokine receptor 4

ameliorates

associated with colorectal cancer; human cells in mouse model
associated with osteosarcoma and melanoma
associated with nasopharynx carcinoma; human cells in mouse model

PMID:16000558 PMID:18071913 PMID:26498029 PMID:31938138

RGD:151665329 RGD:151893515 RGD:152023752 RGD:152177473

NCBI chr2B:23,744,271...23,748,106
Ensembl chr2B:140,181,829...140,189,647

G

discoidin domain receptor tyrosine kinase 1

NCBI chr 6:30,625,871...30,645,066
Ensembl chr 6:31,496,047...31,513,455

G

discoidin domain receptor tyrosine kinase 2

exacerbates

associated with tongue squamous cell carcinoma;

NCBI chr 1:138,048,730...138,200,426
Ensembl chr 1:141,932,158...141,990,766

G

fatty acid synthase

associated with head and neck squamous cell carcinoma

NCBI chr17:76,483,108...76,503,148
Ensembl chr17:82,187,516...82,205,647

G

FOS like 2, AP-1 transcription factor subunit

human cells in mouse model

NCBI chr2A:28,392,328...28,416,838
Ensembl chr2A:28,485,613...28,498,397

G

hypoxia inducible lipid droplet associated

human cells in mouse model

NCBI chr 7:120,446,572...120,449,174
Ensembl chr 7:133,100,523...133,100,714

G

IQ motif and Sec7 domain ArfGEF 1

human cells in mouse model

NCBI chr 3:12,820,552...13,202,925
Ensembl chr 3:13,167,299...13,235,285

G

integrin subunit alpha V

treatment

human cells in rat model

NCBI chr2B:73,880,962...73,972,486
Ensembl chr2B:191,680,655...191,773,028

G

zinc-alpha-2-glycoprotein

ameliorates

associated with hepatocellular carcinoma;

PMID:26902423 PMID:27993894

RGD:153350132 RGD:153350133

NCBI chr 7:91,999,717...92,009,066
Ensembl chr 7:105,432,782...105,442,219

G

mitogen-activated protein kinase kinase kinase 1

ameliorates

associated with breast carcinoma

NCBI chr 5:57,116,405...57,197,017
Ensembl chr 5:58,745,579...58,826,959

G

mitogen-activated protein kinase kinase kinase 8

ameliorates

associated with clear cell renal cell carcinoma

NCBI chr10:30,579,220...30,607,249
Ensembl chr10:30,933,483...30,960,824

G

NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor

associated with hepatocellular carcinoma

NCBI chr22:10,648,022...10,738,167
Ensembl chr22:28,454,119...28,544,013

G

neurotrophic receptor tyrosine kinase 3

ameliorates

associated with mammary carcinoma

NCBI chr15:66,566,219...66,953,279
Ensembl chr15:85,776,832...86,157,204

G

PAXIP1 associated glutamate rich protein 1

human cells in mouse model

Ensembl chr16:30,186,326...30,190,654

G

protein tyrosine phosphatase receptor type B

treatment

NCBI chr12:68,025,973...68,147,613
Ensembl chr12:70,797,843...70,915,308

G

RPTOR independent companion of MTOR complex 2

human cells in mouse model

PMID:20978191 PMID:29809146

RGD:152995469 RGD:152995516

NCBI chr 5:71,299,215...71,435,290
Ensembl chr 5:76,389,130...76,469,830

G

regulatory associated protein of MTOR complex 1

NCBI chr17:74,973,420...75,389,339
Ensembl chr17:80,705,544...81,118,708

G

splicing factor 3b subunit 4

human cells in mouse model

NCBI chr 1:125,268,113...125,273,405
Ensembl chr 1:128,924,317...128,929,610

G

SRY-box transcription factor 30

ameliorates

NCBI chr 5:153,022,109...153,067,734
Ensembl chr 5:159,640,126...159,737,776

G

SRC proto-oncogene, non-receptor tyrosine kinase

treatment
ameliorates

associated with breast cancer;
associated with nasopharynx carcinoma;

PMID:15753384 PMID:27078847

RGD:150521726 RGD:1581400

NCBI chr20:33,667,614...33,727,126
Ensembl chr20:34,822,271...34,839,634

Lymphatic Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 13

susceptibility

DNA:amplification:cds: (human, male)

NCBI chr 7:48,812,624...49,288,605
Ensembl chr 7:48,920,381...49,393,235

G

ADAM metallopeptidase domain 28

associated with breast cancer;DNA:hypermethylation:

NCBI chr 8:23,549,892...23,623,859
Ensembl chr 8:20,474,029...20,540,692

G

adhesion G protein-coupled receptor B1

disease_progression

associated with stomach cancer;

NCBI chr 8:139,154,065...139,251,115
Ensembl chr 8:142,220,827...142,301,070

G

activation induced cytidine deaminase

associated with stomach cancer;protein:increased expression:stomach (human)

NCBI chr12:8,688,392...8,699,008
Ensembl chr12:8,904,273...8,913,917

G

angiopoietin like 4

CTD Direct Evidence: therapeutic

NCBI chr19:7,649,429...7,660,154
Ensembl chr19:8,499,858...8,510,148

G

annexin A1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:51,647,404...51,665,990
Ensembl chr 9:71,929,728...71,948,779

G

aquaporin 3 (Gill blood group)

CTD Direct Evidence: marker/mechanism

NCBI chr 9:33,221,989...33,228,469
Ensembl chr 9:34,032,983...34,039,438

G

Rho GTPase activating protein 5

associated with nasopharynx carcinoma;mRNA, protein:increased expression: epithelium of nasopharynx

NCBI chr14:12,844,042...12,934,411
Ensembl chr14:31,036,511...31,125,349

G

ASXL transcriptional regulator 1

associated with colorectal cancer

NCBI chr20:28,647,004...28,727,865
Ensembl chr20:29,774,582...29,850,453

G

AXL receptor tyrosine kinase

associated Pancreatic Neoplasms

NCBI chr19:38,211,555...38,254,464
Ensembl chr19:46,719,615...46,761,747

G

BAG cochaperone 1

disease_progression

associated with Breast Neoplasms:protein:increased expression:breast

NCBI chr 9:33,033,267...33,043,013
Ensembl chr 9:33,841,449...33,851,167

G

BMP and activin membrane bound inhibitor

associated with stomach cancer; protein:increased expression: :

NCBI chr10:28,833,690...28,839,164
Ensembl chr10:29,187,857...29,193,324

G

BarH like homeobox 2

associated with oral squamous cell carcinoma; mRNA:decreased expression:mouth mucosa

NCBI chr 1:93,373,317...93,378,667
Ensembl chr 1:92,121,017...92,126,036

G

BCL2 apoptosis regulator

associated with Breast Neoplasms;protein:increased expression:lymph node

NCBI chr18:56,481,212...56,679,012
Ensembl chr18:59,802,443...59,992,100

G

BCL2 interacting killer

associated with cholangiocarcinoma;DNA:CNV::

NCBI chr22:23,994,256...24,014,244
Ensembl chr22:42,207,149...42,213,022

G

baculoviral IAP repeat containing 5

disease_progression

associated with Cervix Neoplasms;mRNA:splice variant
associated with Breast Neoplasms

PMID:17285241 PMID:17877643

RGD:2293098 RGD:2293103

NCBI chr17:72,292,332...72,303,493
Ensembl chr17:77,842,724...77,854,159

G

B-Raf proto-oncogene, serine/threonine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 7:132,651,908...132,855,422
Ensembl chr 7:145,138,510...145,327,115

G

bromodomain containing 7

severity

protein:increased expression:lung:

NCBI chr16:30,576,449...30,630,409
Ensembl chr16:49,463,048...49,514,386

G

basigin (Ok blood group)

disease_progression

associated with Breast Neoplasms

Ensembl chr19:539,815...551,456

G

Bruton tyrosine kinase

disease_progression

associated with lung adenocarcinoma;protein:increased expression:lung (human)

NCBI chr X:90,551,874...90,588,786
Ensembl chr X:100,684,017...100,725,187

G

carbonic anhydrase 9

associated with Cervix Neoplasms

NCBI chr 9:35,525,877...35,533,159
Ensembl chr 9:36,328,303...36,335,340

G

calcium binding protein 39

associated with pancreatic cancer;RNA:increased expression:pancreas

NCBI chr2B:117,965,688...118,074,063
Ensembl chr2B:236,809,549...236,870,646

G

caspase 9

associated with Carcinoma, Non-Small-Cell Lung;DNA:SNP:exon:rs1052576 (human)

NCBI chr 1:14,630,659...14,662,865
Ensembl chr 1:15,624,666...15,656,266

G

caveolin 1

disease_progression

associated with Melanoma

NCBI chr 7:108,497,125...108,533,090
Ensembl chr 7:121,193,424...121,229,655

G

Cbl proto-oncogene

associated with stomach carcinoma;protein:increased expression:stomach

NCBI chr11:114,044,996...114,149,204
Ensembl chr11:117,973,187...118,074,671

G

Cbl proto-oncogene B

associated with stomach carcinoma;

NCBI chr 3:102,752,406...102,966,414
Ensembl chr 3:109,690,120...109,905,191

G

cyclin D2

associated with colorectal cancer;protein:increased expression:colorectum

NCBI chr12:4,385,957...4,417,602
Ensembl chr12:4,309,272...4,335,551

G

cyclin E1

associated with Carcinoma, Transitional Cell;protein:decreased expression

NCBI chr19:26,739,285...26,751,630
Ensembl chr19:35,496,700...35,510,295

G

cyclin H

CTD Direct Evidence: marker/mechanism

NCBI chr 5:27,958,859...27,995,815
Ensembl chr 5:28,094,064...28,116,149

G

C-C motif chemokine receptor 5

associated with Breast Neoplasms;mRNA:increased expression:lymph node

NCBI chr 3:46,273,096...46,278,471
Ensembl chr 3:47,380,321...47,381,379

G

CD274 molecule

CTD Direct Evidence: marker/mechanism

NCBI chr 9:5,269,270...5,289,629
Ensembl chr 9:5,454,391...5,474,402

G

CD40 molecule

associated with breast cancer;DNA:snps:5' utr, intron:c.-1T>C, c.51+914T>G (rs1883832, rs4810485) (human)

NCBI chr20:42,455,711...42,467,139
Ensembl chr20:43,541,619...43,552,994

G

CD44 molecule (IN blood group)

associated with Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms;mRNA, protein:splice variant, increased expression:breast, large intestine, stomach

NCBI chr11:35,110,732...35,258,238
Ensembl chr11:34,985,634...35,079,009

G

cadherin 1

associated with Cervix Neoplasms
associated with Breast Neoplasms

PMID:17649807 PMID:18097581

RGD:2289498 RGD:2296046

NCBI chr16:49,108,745...49,206,347
Ensembl chr16:68,502,584...68,596,488

G

cyclin dependent kinase inhibitor 1A

associated with Oral Squamous Cell Carcinoma;
associated with Eyelid Neoplasms;

PMID:15817070 PMID:19628749

RGD:8661799 RGD:8662374

NCBI chr 6:36,241,405...36,250,032
Ensembl chr 6:37,436,990...37,445,599

G

cyclin dependent kinase inhibitor 1B

associated with non-small cell lung carcinoma
associated with Breast Neoplasms

PMID:12015771 PMID:28601655

RGD:13673921 RGD:2293607

NCBI chr12:12,742,258...12,747,404
Ensembl chr12:13,120,306...13,125,541

G

cyclin dependent kinase inhibitor 2A

CTD Direct Evidence: marker/mechanism

NCBI chr 9:21,803,862...21,831,322

G

claudin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:187,328,629...187,345,360
Ensembl chr 3:195,882,239...195,899,248

G

CLPTM1 like

associated with esophagus squamous cell carcinoma; mRNA:increased expression:esophagus

Ensembl chr 5:1,361,571...1,388,415

G

clusterin

associated with breast cancer;DNA:snp:promoter:g.27611345C>G (rs9331888) (human)

NCBI chr 8:26,867,973...26,884,838
Ensembl chr 8:24,070,053...24,083,523

G

catechol-O-methyltransferase

associated with breast cancer;DNA:missense mutation:cds:p.V108/158M (human)

NCBI chr22:2,704,015...2,731,326
Ensembl chr22:18,375,434...18,402,387

G

C-reactive protein

susceptibility

associated with Breast Neoplasm; DNA:polymorphism: :1846C>T(rs1205)(human)

NCBI chr 1:135,062,102...135,064,402

G

colony stimulating factor 1 receptor

associated with Breast Neoplasms

NCBI chr 5:145,478,725...145,537,858
Ensembl chr 5:151,483,572...151,517,415

G

cytotoxic T-lymphocyte associated protein 4

associated with Prostatic Neoplasms

NCBI chr2B:91,054,917...91,106,234
Ensembl chr2B:209,239,417...209,244,498

G

catenin alpha 1

associated with Breast Neoplasms

NCBI chr 5:134,134,944...134,313,239
Ensembl chr 5:140,261,883...140,438,547

G

catenin beta 1

associated with Breast Neoplasms;protein:decreased expression

NCBI chr 3:41,104,940...41,145,934
Ensembl chr 3:41,373,726...41,414,030

G

C-X-C motif chemokine ligand 12

disease_progression

associated with stomach cancer;mRNA:increased expression:stomach (human)

NCBI chr10:41,296,975...41,384,864
Ensembl chr10:44,552,480...44,564,231

G

C-X-C motif chemokine receptor 4

associated with nasopharynx carcinoma; protein:increased expression:lymph node (human)

NCBI chr2B:23,744,271...23,748,106
Ensembl chr2B:140,181,829...140,189,647

G

discoidin domain receptor tyrosine kinase 1

severity

mRNA, protein:increased expression:mouth (human)
mRNA:increased expression:kidney, lymph nodes (human)

PMID:27020590 PMID:31253192

RGD:151347620 RGD:151347863

NCBI chr 6:30,625,871...30,645,066
Ensembl chr 6:31,496,047...31,513,455

G

discoidin domain receptor tyrosine kinase 2

disease_progression

associated with oral squamous cell carcinoma

NCBI chr 1:138,048,730...138,200,426
Ensembl chr 1:141,932,158...141,990,766

G

DNA methyltransferase 3 beta

associated with Carcinoma, Pancreatic Ductal;

NCBI chr20:29,049,993...29,096,957
Ensembl chr20:30,186,069...30,215,487

G

estrogen receptor binding site associated antigen 9

associated with Prostatic Neoplasm;protein:increased expression:prostate gland, lymph node
associated with Breast Neoplasms;protein:increased expression:breast

PMID:12054692 PMID:12845666 PMID:17187007

RGD:2289847 RGD:2289856 RGD:2298489

NCBI chr 8:106,190,208...106,216,402
Ensembl chr 8:108,335,590...108,361,475

G

epidermal growth factor receptor

treatment

associated with Squamous Cell Carcinoma of the Tongue

NCBI chr 7:55,614,042...55,807,285
Ensembl chr 7:56,046,296...56,111,615

G

euchromatic histone lysine methyltransferase 2

associated with Melanoma;
associated with Esophageal Squamous Cell Carcinoma;

PMID:24658378 PMID:24805087

RGD:9590069 RGD:9590071

NCBI chr 6:31,542,946...31,560,894
Ensembl chr 6:32,429,271...32,451,844

G

EPH receptor A2

protein:increased expression:esophagus (human)

NCBI chr 1:15,259,915...15,292,983
Ensembl chr 1:16,253,513...16,284,787

G

erb-b2 receptor tyrosine kinase 2

disease_progression

associated with Breast Neoplasms;DNA, protein:polymorphism, increased expression:serum:p.I655V
associated with lung adenocarcinoma; protein:increased expression:lung (human)
CTD Direct Evidence: marker/mechanism
associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder

PMID:18097576 PMID:18237248 PMID:21532492 PMID:21966491

RGD:153344600 RGD:2289925 RGD:2289926

NCBI chr17:17,560,337...17,600,808
Ensembl chr17:17,777,434...17,805,862

G

erb-b2 receptor tyrosine kinase 3

associated with Prostatic Neoplasms;protein:increased expression, altered localization:lymph node, nucleus
associated with head and neck squamous cell carcinoma

PMID:17634423 PMID:20604875

RGD:126790467 RGD:2289944

NCBI chr12:32,811,533...32,834,958
Ensembl chr12:33,063,434...33,084,994

G

erb-b2 receptor tyrosine kinase 4

severity
disease_progression

associated with colorectal adenocarcinoma
associated with lung non-small cell carcinoma
associated with oral squamous cell carcinoma

PMID:16507107 PMID:21324275 PMID:27444519

RGD:126781762 RGD:126781766 RGD:126790471

NCBI chr2B:98,625,630...99,795,371
Ensembl chr2B:217,069,644...218,272,006

G

Fas cell surface death receptor

susceptibility

associated with Cervix Neoplasms;DNA:polymorphism:promoter:-1377G>A

NCBI chr10:85,707,457...85,741,539
Ensembl chr10:89,217,949...89,243,612

G

fibroblast growth factor 1

associated with Cervix Neoplasms;mRNA:increased expression:lymph node

NCBI chr 5:137,949,100...138,054,553
Ensembl chr 5:144,056,387...144,078,001

G

fibroblast growth factor receptor 2

associated with breast cancer;DNA:snp:intron:c.109+7033T>A (rs1219648) (human)

NCBI chr10:118,055,854...118,175,440
Ensembl chr10:121,469,735...121,588,815

G

fms related receptor tyrosine kinase 3

disease_progression

associated with Prostatic Neoplasms

NCBI chr13:9,283,747...9,381,553
Ensembl chr13:27,627,178...27,723,940

G

forkhead box A1

associated with lung non-small cell carcinoma; mRNA:increased expression: :

NCBI chr14:18,347,284...18,352,705

G

forkhead box P1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:70,893,933...71,523,892
Ensembl chr 3:72,258,456...72,498,173

G

glutathione peroxidase 3

associated with stomach carcinoma; DNA:hypermethylation:promoter

NCBI chr 5:146,447,939...146,456,476

G

glutamate ionotropic receptor kainate type subunit 2

CTD Direct Evidence: marker/mechanism

NCBI chr 6:98,720,430...99,903,582
Ensembl chr 6:103,334,707...103,783,092

G

high mobility group box 1

associated with Adenocarcinoma, Colon

NCBI chr13:11,737,942...11,894,923
Ensembl chr13:30,174,899...30,179,527

G

intercellular adhesion molecule 1

associated with Breast Neoplasms

NCBI chr19:9,821,402...9,837,021
Ensembl chr19:10,484,414...10,500,605

G

immediate early response 2

NCBI chr19:12,714,804...12,718,213
Ensembl chr19:13,452,239...13,452,910

G

interleukin 13

associated with Melanoma, Cutaneous Malignant;mRNA:increased expression:lymph node

NCBI chr 5:128,073,863...128,078,453
Ensembl chr 5:134,235,788...134,240,548

G

interleukin 18

associated with Breast Neoplasms;protein:increased expression:serum

NCBI chr11:107,024,376...107,045,194
Ensembl chr11:110,867,586...110,888,371

G

inhibitor of growth family member 4

CTD Direct Evidence: therapeutic

NCBI chr12:6,782,402...6,795,035
Ensembl chr12:6,698,843...6,710,955

G

IQ motif and Sec7 domain ArfGEF 1

disease_progression

associated with lung adenocarcinoma; protein:increased expression:lung (human)

NCBI chr 3:12,820,552...13,202,925
Ensembl chr 3:13,167,299...13,235,285

G

integrin subunit beta 1

associated with non-small cell lung carcinoma,

NCBI chr10:33,023,573...33,081,384
Ensembl chr10:33,608,978...33,644,031

G

potassium inwardly rectifying channel subfamily J member 12

CTD Direct Evidence: marker/mechanism

NCBI chr17:30,190,240...30,233,740

G

kinase insert domain receptor

treatment

associated with Squamous Cell Carcinoma of the Tongue

NCBI chr 4:68,813,894...68,861,018
Ensembl chr 4:75,377,375...75,427,109

G

KiSS-1 metastasis suppressor

CTD Direct Evidence: therapeutic

G

KLF transcription factor 7

CTD Direct Evidence: therapeutic

NCBI chr2B:94,307,334...94,399,553
Ensembl chr2B:212,448,337...212,525,403

G

lysine methyltransferase 2D

associated with stomach cancer

NCBI chr12:39,689,463...39,731,904
Ensembl chr12:40,575,083...40,608,661

G

laminin subunit gamma 2

associated with lung squamous cell carcinoma;

NCBI chr 1:158,697,084...158,763,209
Ensembl chr 1:162,862,785...162,921,864

G

solute carrier family 22 member 10

CTD Direct Evidence: marker/mechanism

NCBI chr11:58,573,286...58,668,946
Ensembl chr11:61,997,429...62,018,738

G

cytochrome c

associated with non-small cell lung carcinoma; protein:decreased expression:serum

NCBI chr 7:25,784,900...25,791,598
Ensembl chr 7:25,396,013...25,398,549

G

leucine rich repeat containing 59

CTD Direct Evidence: marker/mechanism

NCBI chr17:44,475,661...44,492,021
Ensembl chr17:49,349,738...49,366,039

G

macrophage immunometabolism regulator

CTD Direct Evidence: marker/mechanism

NCBI chr 5:98,612,892...98,632,854
Ensembl chr 5:104,330,232...104,330,852

G

MET proto-oncogene, receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 7:108,646,278...108,772,238
Ensembl chr 7:121,365,438...121,468,159

G

matrix metallopeptidase 2

disease_progression

associated with Carcinoma, Ductal, Breast
associated with Tongue Neoplasms

PMID:23107277 PMID:23280016

RGD:8547824 RGD:8655998

NCBI chr16:35,711,866...35,738,881
Ensembl chr16:54,812,694...54,844,279

G

matrix metallopeptidase 3

associated with breast cancer;DNA:deletion:promoter:-1170_-1172delA (human)

NCBI chr11:97,776,729...97,784,549
Ensembl chr11:101,267,566...101,275,354

G

matrix metallopeptidase 9

disease_progression

associated with Endometrial Neoplasms;protein:increased expression:endometrium
associated with Tongue Neoplasms
associated with Carcinoma, Non-Small-Cell Lung;protein:increased expression:serum

PMID:12487935 PMID:20704821 PMID:23107277

RGD:2298523 RGD:5129215 RGD:8547824

NCBI chr20:42,346,305...42,354,018
Ensembl chr20:43,432,389...43,440,129

G

mutS homolog 2

associated with laryngeal squamous cell carcinoma

NCBI chr2A:47,524,468...47,602,376
Ensembl chr2A:48,447,207...48,554,461

G

mesothelin

CTD Direct Evidence: marker/mechanism

Ensembl chr16:777,146...783,449

G

metastasis associated 1

associated with Carcinoma, Non-Small-Cell Lung;mRNA:increased expression:lung

NCBI chr14:86,058,412...86,111,736

G

mechanistic target of rapamycin kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:9,871,700...10,028,704
Ensembl chr 1:11,093,765...11,249,841

G

mucin 1, cell surface associated

associated with Gallbladder Neoplasms;protein:altered localization:gallbladder
associated with Common Bile Duct Neoplasms
associated with Carcinoma, Renal Cell;
associated with Esophageal Neoplasms

PMID:10390012 PMID:11295067 PMID:16222735 PMID:21339746

RGD:2324649 RGD:2324860 RGD:7245968 RGD:7349383

NCBI chr 1:130,533,508...130,537,866
Ensembl chr 1:134,141,969...134,145,850

G

mucin 5AC, oligomeric mucus/gel-forming

associated with chloangiocarcinoma;protein:increased expression:bile duct

NCBI chr11:1,191,223...1,234,373

G

neural cell adhesion molecule 1

NCBI chr11:107,845,507...108,160,441
Ensembl chr11:111,925,677...112,000,401

G

NME/NM23 nucleoside diphosphate kinase 1

associated with Cervix Neoplasms; associated with Endometrial Neoplasms
associated with Breast Neoplasms

PMID:8102131 PMID:8855975 PMID:9036878

RGD:2299061 RGD:2299062 RGD:2299077

NCBI chr17:45,243,588...45,252,135
Ensembl chr17:50,113,622...50,131,636

G

NME/NM23 nucleoside diphosphate kinase 2

associated with Cervix Neoplasms; associated with Endometrial Neoplasms

NCBI chr17:45,255,982...45,261,541

G

nitric oxide synthase 3

susceptibility

associated with Breast Neoplasms;DNA:polymorphisms:promoter, exon:-786T>C,p.E298D (human)

NCBI chr 7:142,577,334...142,600,702
Ensembl chr 7:154,730,009...154,755,233

G

8-oxoguanine DNA glycosylase

associated with breast cancer;DNA:missense mutation:cds:p.S326C (rs1052133) (human)

NCBI chr 3:9,702,311...9,742,283
Ensembl chr 3:9,940,955...9,947,335

G

PAXIP1 associated glutamate rich protein 1

disease_progression

protein:decreased expression:esophagus (human)

Ensembl chr16:30,186,326...30,190,654

G

platelet derived growth factor subunit A

associated with Breast Neoplasms;mRNA:increased expression:breast

NCBI chr 7:648,722...672,023

G

platelet derived growth factor subunit B

associated with Breast Neoplasms;mRNA:increased expression:lymph node

NCBI chr22:20,127,223...20,148,407
Ensembl chr22:37,944,018...37,964,883

G

3-phosphoinositide dependent protein kinase 1

associated with non-small cell lung carcinoma;mRNA:increased expression:blood serum

NCBI chr16:1,394,447...1,463,735

G

podoplanin

associated with Breast Neoplasms
associated with Cervix Neoplasms

PMID:16528371 PMID:18165897

RGD:2292231 RGD:2292237

NCBI chr 1:12,728,569...12,759,781
Ensembl chr 1:13,728,233...13,759,584

G

phosphatidylethanolamine binding protein 1

associated with Breast Neoplasms
associated with Cervix Neoplasms

PMID:16243812 PMID:18191186

RGD:2302867 RGD:2302868

NCBI chr12:115,716,953...115,726,412
Ensembl chr12:119,093,952...119,105,054

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

associated with Colorectal Neoplasms

NCBI chr 3:176,182,765...176,272,024
Ensembl chr 3:184,355,785...184,441,977

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta

associated with Colorectal Neoplasms

NCBI chr 3:135,685,120...135,867,096
Ensembl chr 3:143,288,563...143,431,314

G

phosphatidylinositol-4-phosphate 5-kinase type 1 alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 1:126,547,793...126,598,618
Ensembl chr 1:130,195,974...130,246,198

G

POU class 5 homeobox 1

associated with Seminoma; associated with Carcinoma, Embryonal

NCBI chr 6:30,910,421...30,916,465
Ensembl chr 6:31,775,343...31,781,426

G

peroxisome proliferator activated receptor gamma

associated with Cholangiocarcinoma;protein:increased expression:bile duct epithelium

NCBI chr 3:12,215,322...12,361,669
Ensembl chr 3:12,622,397...12,705,060

G

phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1

associated with Prostatic Neoplasms

NCBI chr20:44,965,850...45,169,891
Ensembl chr20:46,033,937...46,226,500

G

phosphatase and tensin homolog

associated with Breast Neoplasms
associated with Prostatic Neoplasms;protein:decreased expression:prostate

PMID:17163422 PMID:17919877

RGD:2292499 RGD:2292507

NCBI chr10:84,587,841...84,689,043
Ensembl chr10:88,093,539...88,194,605

G

prostaglandin-endoperoxide synthase 2

associated with Biliary Tract Neoplasms
associated with carcinoma, non-small-cell lung; DNA:SNP: :929G>C(human)
associated with Breast Neoplasms

PMID:18159174 PMID:18353210 PMID:20016751

RGD:2300128 RGD:2317165 RGD:5135471

NCBI chr 1:162,205,534...162,214,130
Ensembl chr 1:166,355,845...166,364,519

G

protein tyrosine kinase 2

associated with lung squamous cell carcinoma; protein:increased tyrosine phosphorylation:lymph node

NCBI chr 8:137,330,777...137,677,306
Ensembl chr 8:140,412,773...140,684,898

G

protein tyrosine phosphatase non-receptor type 13

associated with lung squamous cell carcinoma; protein:decreased expression:lymph node

NCBI chr 4:78,893,598...79,118,745
Ensembl chr 4:89,623,271...89,847,616

G

receptor activity modifying protein 2

disease_progression

associated with colorectal cancer; protein:increased expression:lymph node (human)

NCBI chr17:14,554,888...14,557,175
Ensembl chr17:14,779,666...14,781,481

G

receptor activity modifying protein 3

associated with colorectal cancer; protein:increased expression:lymph node (human)

NCBI chr 7:45,871,687...45,898,159
Ensembl chr 7:45,937,607...45,966,041

G

Ras association domain family member 2

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,804,802...4,845,633
Ensembl chr20:4,603,414...4,641,529

G

RNA binding motif protein 10

associated with lung adenocarcinoma;DNA:missense mutation:exon:p.R241C (c.763C>T) (human)

NCBI chr X:39,582,480...39,623,749
Ensembl chr X:47,440,815...47,481,204

G

RELA proto-oncogene, NF-kB subunit

associated with Prostatic Neoplasms;protein:altered localization:nucleus, prostate gland

NCBI chr11:61,012,839...61,022,225
Ensembl chr11:64,347,859...64,356,868

G

ret proto-oncogene

associated with Pancreatic Neoplasms

NCBI chr10:40,050,396...40,103,629
Ensembl chr10:43,249,468...43,284,331

G

ras homolog family member A

associated with colorectal cancer
associated with Bladder Neoplasms;protein:increased expression:lymph node

PMID:12855641 PMID:17597401

RGD:13432052 RGD:2298872

NCBI chr 3:49,282,009...49,339,887

G

RPTOR independent companion of MTOR complex 2

associated with breast ductal carcinoma; protein:increased expression:breast tumor, lymph node (human)

NCBI chr 5:71,299,215...71,435,290
Ensembl chr 5:76,389,130...76,469,830

G

stratifin

CTD Direct Evidence: marker/mechanism

NCBI chr 1:26,126,212...26,127,761
Ensembl chr 1:27,182,834...27,183,580

G

S-phase kinase associated protein 2

associated with Endometrial Neoplasms;protein:increased expression:endometrium

NCBI chr 5:74,179,608...74,211,563
Ensembl chr 5:79,461,018...79,492,311

G

solute carrier family 7 member 5

severity

associated with gastric adenocarcinoma;protein:increased expression: :
associated with stomach carcinoma

PMID:21501294 PMID:25908107

RGD:11052781 RGD:151361203

NCBI chr16:68,512,407...68,552,763

G

SMAD family member 4

associated with Breast Neoplasms

NCBI chr18:44,402,112...44,456,779
Ensembl chr18:47,764,568...47,797,359

G

smoothened, frizzled class receptor

associated with colorectal cancer

NCBI chr 7:121,143,968...121,168,873
Ensembl chr 7:133,668,304...133,693,048

G

synuclein gamma

NCBI chr10:83,383,566...83,391,064

G

suppressor of cytokine signaling 2

associated with Prostatic Neoplasms

NCBI chr12:91,115,319...91,134,191
Ensembl chr12:94,514,455...94,520,748

G

suppressor of cytokine signaling 3

associated with Breast Neoplasms

NCBI chr17:72,433,206...72,436,500
Ensembl chr17:77,983,389...77,984,066

G

superoxide dismutase 2

disease_progression

CTD Direct Evidence: marker/mechanism
associated with tongue neoplasms;

PMID:10853026 PMID:19381893 PMID:20618948

NCBI chr 6:157,562,814...157,610,155
Ensembl chr 6:162,576,082...162,589,960

G

SRY-box transcription factor 2

disease_progression

associated with Breast Neoplasms

NCBI chr 3:178,744,881...178,747,392
Ensembl chr 3:186,922,705...186,923,662

G

SRC proto-oncogene, non-receptor tyrosine kinase

associated with colon adenocarcinoma,

NCBI chr20:33,667,614...33,727,126
Ensembl chr20:34,822,271...34,839,634

G

ST14 transmembrane serine protease matriptase

associated with Endometrial Neoplasms

NCBI chr11:125,001,771...125,021,371
Ensembl chr11:128,888,124...128,913,559

G

signal transducer and activator of transcription 3

CTD Direct Evidence: marker/mechanism

NCBI chr17:14,928,689...15,003,644
Ensembl chr17:15,152,358...15,227,067

G

serine/threonine kinase 11

associated with Breast Neoplasms;protein:decreased expression

Ensembl chr19:1,188,537...1,210,677

G

telomerase reverse transcriptase

disease_progression

associated with lung non-small cell carcinoma;

Ensembl chr 5:1,300,960...1,338,872

G

TIMP metallopeptidase inhibitor 1

associated with Endometrial Neoplasms;protein:increased expression:endometrium

NCBI chr X:40,018,190...40,022,636
Ensembl chr X:47,914,906...47,919,419

G

TIMP metallopeptidase inhibitor 3

associated with Breast Neoplasms;mRNA:increased expression:breast

NCBI chr22:13,811,297...13,872,799
Ensembl chr22:31,662,562...31,723,964

G

TIMP metallopeptidase inhibitor 4

associated with Breast Neoplasms;mRNA:increased expression:breast

NCBI chr 3:12,079,195...12,087,485
Ensembl chr 3:12,425,429...12,433,192

G

toll like receptor 4

associated with Carcinoma, Ductal, Breast;

NCBI chr 9:88,827,495...88,840,458
Ensembl chr 9:117,180,550...117,190,711

G

tumor protein p53

associated with Penile Neoplasms
associated with Breast Neoplasms;DNA:missense mutation, duplication:cds, intron:p.R72P
associated with Carcinoma, Squamous Cell;

PMID:18059331 PMID:18230179 PMID:18268397

RGD:2290533 RGD:2290534 RGD:8547790

NCBI chr17:7,699,449...7,717,812
Ensembl chr17:7,684,922...7,706,120

G

tumor protein p53 binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr15:22,364,696...22,472,499
Ensembl chr15:40,519,012...40,626,741

G

tRNA methyltransferase 11 homolog

CTD Direct Evidence: marker/mechanism

NCBI chr 6:123,770,783...123,825,179
Ensembl chr 6:127,888,697...127,941,505

G

TSC complex subunit 2

associated with Breast Neoplasms

NCBI chr16:615,776...655,411
Ensembl chr16:2,135,696...2,175,569

G

thyroid stimulating hormone receptor

CTD Direct Evidence: marker/mechanism

NCBI chr14:61,517,767...61,708,241
Ensembl chr14:80,718,433...80,905,890

G

transthyretin

associated with colorectal cancer;protein:decreased expresion:blood serum (human)

NCBI chr18:24,809,707...24,816,713
Ensembl chr18:28,407,893...28,414,960

G

thymidine phosphorylase

associated with Cholangiocarcinoma
associated with Breast Neoplasms

PMID:10685502 PMID:11927969

RGD:2293725 RGD:2325027

NCBI chr22:30,772,088...30,776,618

G

vascular endothelial growth factor A

associated with Breast neoplasms;
associated with Cervix Neoplasms

PMID:17597103 PMID:19783962

RGD:2315454 RGD:7421574

NCBI chr 6:43,361,053...43,377,366
Ensembl chr 6:44,650,365...44,666,353

G

vascular endothelial growth factor C

exacerbates
disease_progression

associated with Cervix Neoplasms
associated with pancreatic adenocarcinoma;protein:increased expression:pancreas (human)
associated with Prostatic Neoplasms
associated with thyroid diseases;mRNA:increased expression:thyroid gland:
associated with Breast Neoplasms
associated with Lymphatic Metastasis;
associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder

PMID:12203051 PMID:15289890 PMID:17034609 PMID:18061373 PMID:19589137 More...

RGD:155630642 RGD:2315469 RGD:2315474 RGD:2315475 RGD:2315484 RGD:7483611 RGD:7488946

NCBI chr 4:168,870,941...168,999,160
Ensembl chr 4:181,104,737...181,236,030

G

vascular endothelial growth factor D

associated with Cervix Neoplasms
associated with Breast Neoplasms

PMID:17951197 PMID:19589137

RGD:2315475 RGD:2315480

NCBI chr X:7,972,227...8,011,263
Ensembl chr X:15,254,945...15,293,704

G

WD repeat containing antisense to TP53

associated with lung non-small cell carcinoma;
associated with esophagus squamous cell carcinoma;

PMID:24626331 PMID:31281482

RGD:21081513 RGD:21081532

NCBI chr17:7,715,897...7,735,873
Ensembl chr17:7,707,221...7,723,394

Neoplasm Invasiveness

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aconitase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:32,157,763...32,225,116
Ensembl chr 9:32,967,993...33,035,177

G

actin beta

CTD Direct Evidence: marker/mechanism

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

CTD Direct Evidence: marker/mechanism

NCBI chr21:13,270,668...13,279,217
Ensembl chr21:26,656,370...26,665,485

G

AHNAK nucleoprotein

CTD Direct Evidence: marker/mechanism

NCBI chr11:57,791,927...57,904,277
Ensembl chr11:61,149,485...61,249,137

G

aryl hydrocarbon receptor

CTD Direct Evidence: therapeutic

PMID:25826687 PMID:27752740

NCBI chr 7:17,949,254...17,998,737
Ensembl chr 7:17,278,637...17,326,171

G

aldo-keto reductase family 1 member B10

CTD Direct Evidence: marker/mechanism

NCBI chr 7:126,486,012...126,499,852
Ensembl chr 7:138,992,835...139,006,003

G

aldolase, fructose-bisphosphate A

CTD Direct Evidence: marker/mechanism

G

alkB homolog 8, tRNA methyltransferase

CTD Direct Evidence: marker/mechanism

NCBI chr11:102,390,687...102,456,357
Ensembl chr11:105,872,588...105,937,472

G

arachidonate 5-lipoxygenase

CTD Direct Evidence: marker/mechanism

NCBI chr10:42,461,398...42,531,576
Ensembl chr10:45,639,946...45,710,016

G

alpha-1-microglobulin/bikunin precursor

CTD Direct Evidence: therapeutic

NCBI chr 9:85,157,680...85,176,253
Ensembl chr 9:113,525,835...113,543,422

G

angiomotin like 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:89,743,625...89,890,334
Ensembl chr11:93,278,464...93,413,197

G

angiopoietin 1

associated with Mammary Neoplasms, Animal;mRNA:increased expression:mammary gland

NCBI chr 8:103,893,234...104,137,661
Ensembl chr 8:106,042,041...106,286,783

G

angiopoietin like 4

CTD Direct Evidence: therapeutic

NCBI chr19:7,649,429...7,660,154
Ensembl chr19:8,499,858...8,510,148

G

annexin A1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:51,647,404...51,665,990
Ensembl chr 9:71,929,728...71,948,779

G

annexin A2

CTD Direct Evidence: marker/mechanism

NCBI chr15:39,322,303...39,371,565
Ensembl chr15:57,625,425...57,674,250

G

ARF GTPase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:203,484,803...203,501,395
Ensembl chr 1:208,695,615...208,712,105

G

AXL receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr19:38,211,555...38,254,464
Ensembl chr19:46,719,615...46,761,747

G

BCAR1 scaffold protein, Cas family member

CTD Direct Evidence: marker/mechanism

NCBI chr16:55,798,578...55,838,448
Ensembl chr16:75,150,122...75,188,775

G

BRMS1 transcriptional repressor and anoikis regulator

CTD Direct Evidence: therapeutic

NCBI chr11:61,703,021...61,710,784
Ensembl chr11:65,028,407...65,036,163

G

basigin (Ok blood group)

CTD Direct Evidence: marker/mechanism

Ensembl chr19:539,815...551,456

G

calreticulin

CTD Direct Evidence: marker/mechanism

NCBI chr19:12,501,013...12,506,909
Ensembl chr19:13,242,900...13,249,416

G

calumenin

CTD Direct Evidence: marker/mechanism

NCBI chr 7:120,691,092...120,723,303
Ensembl chr 7:133,223,269...133,247,167

G

catalase

CTD Direct Evidence: therapeutic

PMID:21749277 PMID:22580338

NCBI chr11:34,413,253...34,446,831
Ensembl chr11:34,289,603...34,323,160

G

C-C motif chemokine ligand 2

CTD Direct Evidence: marker/mechanism

PMID:25199511 PMID:32512068

NCBI chr17:22,528,154...22,530,091
Ensembl chr17:22,820,890...22,823,384

G

C-C motif chemokine ligand 5

CTD Direct Evidence: marker/mechanism

NCBI chr17:20,915,198...20,923,530
Ensembl chr17:21,210,798...21,219,172

G

CD82 molecule

CTD Direct Evidence: therapeutic

NCBI chr11:44,526,010...44,581,560
Ensembl chr11:45,020,319...45,075,876

G

cadherin 1

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:19839049 PMID:22580338

NCBI chr16:49,108,745...49,206,347
Ensembl chr16:68,502,584...68,596,488

G

cadherin 2

CTD Direct Evidence: marker/mechanism

NCBI chr18:21,210,001...21,435,919
Ensembl chr18:24,812,019...25,008,325

G

cyclin dependent kinase inhibitor 2A

CTD Direct Evidence: marker/mechanism

NCBI chr 9:21,803,862...21,831,322

G

cofilin 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:61,215,092...61,218,628
Ensembl chr11:64,544,275...64,550,806

G

chitinase 3 like 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:178,778,081...178,789,704
Ensembl chr 1:183,075,312...183,083,229

G

chromosome segregation 1 like

CTD Direct Evidence: marker/mechanism

NCBI chr20:45,386,124...45,436,283
Ensembl chr20:46,452,485...46,502,207

G

cystatin B

CTD Direct Evidence: marker/mechanism

PMID:19747051 PMID:22287159

NCBI chr21:30,030,359...30,032,899

G

C-terminal binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:121,550,194...121,722,828
Ensembl chr10:125,814,926...125,901,248

G

catenin beta 1

CTD Direct Evidence: marker/mechanism

PMID:23707762 PMID:26990689

NCBI chr 3:41,104,940...41,145,934
Ensembl chr 3:41,373,726...41,414,030

G

cathepsin B

CTD Direct Evidence: marker/mechanism

PMID:19700239 PMID:19747051

NCBI chr 8:7,333,498...7,359,264

G

cathepsin D

CTD Direct Evidence: marker/mechanism

NCBI chr11:1,789,326...1,800,524

G

cathepsin S

CTD Direct Evidence: marker/mechanism

NCBI chr 1:126,084,249...126,118,221
Ensembl chr 1:129,733,996...129,768,318

G

cytosolic thiouridylase subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:48,065,741...48,075,758

G

cytosolic thiouridylase subunit 2

CTD Direct Evidence: marker/mechanism

NCBI chr16:69,419,811...69,428,500
Ensembl chr16:89,079,132...89,088,231

G

C-X-C motif chemokine ligand 12

CTD Direct Evidence: marker/mechanism

PMID:19700239 PMID:25231984 PMID:25753200

NCBI chr10:41,296,975...41,384,864
Ensembl chr10:44,552,480...44,564,231

G

C-X-C motif chemokine ligand 8

CTD Direct Evidence: marker/mechanism

NCBI chr 4:50,452,857...50,456,015
Ensembl chr 4:56,286,708...56,288,083

G

C-X-C motif chemokine receptor 4

CTD Direct Evidence: marker/mechanism

NCBI chr2B:23,744,271...23,748,106
Ensembl chr2B:140,181,829...140,189,647

G

cytochrome P450 family 2 subfamily E member 1

CTD Direct Evidence: marker/mechanism

Ensembl chr10:134,839,025...134,852,719

G

DEK proto-oncogene

CTD Direct Evidence: marker/mechanism

PMID:21291860 PMID:27811057

NCBI chr 6:18,071,928...18,112,245
Ensembl chr 6:18,427,844...18,465,606

G

distal-less homeobox 4

CTD Direct Evidence: marker/mechanism

NCBI chr17:44,055,326...44,061,687
Ensembl chr17:48,929,684...48,935,066

G

dystrophin

CTD Direct Evidence: marker/mechanism

NCBI chr X:23,728,650...26,338,849
Ensembl chr X:31,282,415...33,492,733

G

DNA methyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:9,681,847...9,745,334
Ensembl chr19:10,342,478...10,406,972

G

endothelin receptor type B

CTD Direct Evidence: marker/mechanism

NCBI chr13:59,112,349...59,136,615
Ensembl chr13:78,153,020...78,177,286

G

eukaryotic translation elongation factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:3,000,608...3,009,918
Ensembl chr19:3,950,772...3,960,172

G

epidermal growth factor

CTD Direct Evidence: marker/mechanism

PMID:15802018 PMID:22869556 PMID:23064031 PMID:24587105 PMID:27634460

NCBI chr 4:102,410,724...102,509,691
Ensembl chr 4:112,977,565...113,076,460

G

epidermal growth factor receptor

CTD Direct Evidence: marker/mechanism

PMID:18844224 PMID:23867902

NCBI chr 7:55,614,042...55,807,285
Ensembl chr 7:56,046,296...56,111,615

G

eukaryotic translation initiation factor 4E

CTD Direct Evidence: marker/mechanism

NCBI chr 4:91,268,463...91,329,800
Ensembl chr 4:101,941,142...101,994,809

G

elongator acetyltransferase complex subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:80,020,131...80,085,076
Ensembl chr 9:108,194,011...108,258,500

G

elongator acetyltransferase complex subunit 3

CTD Direct Evidence: marker/mechanism

NCBI chr 8:27,370,360...27,470,169
Ensembl chr 8:24,570,410...24,669,941

G

engrailed homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr2B:5,798,557...5,804,368

G

enolase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:7,619,490...7,637,558
Ensembl chr 1:8,855,074...8,873,215

G

endothelial PAS domain protein 1

CTD Direct Evidence: marker/mechanism

PMID:26735578 PMID:30090327

NCBI chr2A:46,403,411...46,492,734
Ensembl chr2A:47,332,308...47,421,560

G

erythropoietin

CTD Direct Evidence: marker/mechanism

NCBI chr 7:92,747,671...92,750,886
Ensembl chr 7:106,148,062...106,150,974

G

erythropoietin receptor

CTD Direct Evidence: marker/mechanism

NCBI chr19:10,925,148...10,931,955
Ensembl chr19:11,635,248...11,642,383

G

EGFR pathway substrate 8, signaling adaptor

CTD Direct Evidence: marker/mechanism

NCBI chr12:15,617,536...15,788,537
Ensembl chr12:16,013,276...16,076,117

G

estrogen receptor 1

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:26990689 PMID:27366082 PMID:35044086

NCBI chr 6:149,507,599...149,918,523
Ensembl chr 6:154,317,002...154,631,551

G

family with sequence similarity 83 member A

CTD Direct Evidence: marker/mechanism

NCBI chr 8:119,877,517...119,905,848
Ensembl chr 8:122,633,373...122,661,709

G

fibroblast growth factor receptor 4

ClinVar Annotator: match by term: Cancer progression and tumor cell motility

PMID:11830541 PMID:25741868 PMID:26675719 PMID:33116287

NCBI chr 5:172,386,443...172,400,271
Ensembl chr 5:179,454,995...179,467,605

G

fibronectin 1

CTD Direct Evidence: marker/mechanism

NCBI chr2B:102,623,568...102,698,747
Ensembl chr2B:221,208,431...221,284,003

G

forkhead box P1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:70,893,933...71,523,892
Ensembl chr 3:72,258,456...72,498,173

G

ferritin heavy chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:57,329,163...57,332,248

G

ferritin light chain

CTD Direct Evidence: marker/mechanism

NCBI chr19:45,966,431...45,968,015
Ensembl chr19:54,788,854...54,790,465

G

GRB2 associated binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr11:73,275,360...73,478,272
Ensembl chr11:76,896,691...76,967,007

G

glycine rich extracellular protein 1

CTD Direct Evidence: marker/mechanism

G

histone deacetylase 3

CTD Direct Evidence: marker/mechanism

NCBI chr 5:136,981,790...136,997,786
Ensembl chr 5:143,094,406...143,110,322

G

hepatocyte growth factor

CTD Direct Evidence: marker/mechanism

PMID:9932610 PMID:15654357

NCBI chr 7:73,667,618...73,738,960
Ensembl chr 7:87,327,798...87,397,811

G

hypoxia inducible factor 1 subunit alpha

CTD Direct Evidence: marker/mechanism

PMID:12811834 PMID:29501572

NCBI chr14:42,295,691...42,348,478
Ensembl chr14:60,552,374...60,604,885

G

high mobility group AT-hook 2

CTD Direct Evidence: marker/mechanism

NCBI chr12:22,954,946...23,096,623

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:82,778,489...82,798,987
Ensembl chr 1:117,775,770...117,796,679

G

heme oxygenase 1

CTD Direct Evidence: therapeutic

NCBI chr22:16,388,368...16,401,289
Ensembl chr22:34,230,825...34,244,063

G

homeobox B13

CTD Direct Evidence: marker/mechanism

NCBI chr17:8,807,988...8,810,362
Ensembl chr17:8,994,224...8,996,598

G

homeobox B3

CTD Direct Evidence: marker/mechanism

NCBI chr17:8,946,441...8,987,876
Ensembl chr17:9,147,784...9,171,021

G

heparanase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:40,863,491...40,905,693
Ensembl chr 4:46,709,621...46,755,157

G

HRas proto-oncogene, GTPase

CTD Direct Evidence: marker/mechanism

NCBI chr11:537,488...540,810
Ensembl chr11:568,305...571,078

G

inhibitor of DNA binding 4

CTD Direct Evidence: marker/mechanism

NCBI chr 6:19,665,197...19,668,517

G

insulin like growth factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:99,986,887...100,066,773
Ensembl chr12:103,385,911...103,462,177

G

interleukin 1 beta

CTD Direct Evidence: marker/mechanism

NCBI chr2A:89,216,313...89,223,358
Ensembl chr2A:113,846,306...113,853,424

G

interleukin 1 receptor antagonist

CTD Direct Evidence: therapeutic

NCBI chr2A:88,991,646...89,008,013
Ensembl chr2A:114,061,182...114,078,839

G

interleukin 6

CTD Direct Evidence: marker/mechanism

PMID:26101800 PMID:26284488

NCBI chr 7:23,415,922...23,420,767

G

insulin

CTD Direct Evidence: marker/mechanism

NCBI chr11:2,200,785...2,202,579
Ensembl chr11:2,218,117...2,231,666

G

iron responsive element binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr15:57,367,314...57,430,322
Ensembl chr15:76,331,610...76,394,476

G

integrin subunit alpha 5

CTD Direct Evidence: marker/mechanism

NCBI chr12:34,326,182...34,350,050
Ensembl chr12:35,052,994...35,075,835

G

integrin subunit beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:33,023,573...33,081,384
Ensembl chr10:33,608,978...33,644,031

G

inositol-tetrakisphosphate 1-kinase

CTD Direct Evidence: marker/mechanism

NCBI chr14:73,573,020...73,750,109
Ensembl chr14:92,909,785...93,087,773

G

potassium voltage-gated channel subfamily D member 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:112,277,018...112,751,896
Ensembl chr 7:124,966,816...125,437,430

G

lysine demethylase 1A

CTD Direct Evidence: marker/mechanism

NCBI chr 1:22,205,624...22,269,571
Ensembl chr 1:23,153,066...23,217,692

G

keratin 19

CTD Direct Evidence: marker/mechanism

NCBI chr17:15,788,355...15,793,127
Ensembl chr17:16,006,608...16,010,782

G

keratin 7

CTD Direct Evidence: marker/mechanism

NCBI chr12:36,514,021...36,529,721
Ensembl chr12:37,291,244...37,307,341

G

lactate dehydrogenase B

CTD Direct Evidence: marker/mechanism

NCBI chr12:64,640,994...64,663,418
Ensembl chr12:67,245,130...67,267,487

G

lymphoid enhancer binding factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:100,552,959...100,674,156
Ensembl chr 4:111,125,312...111,245,980

G

lin-28 homolog A

CTD Direct Evidence: marker/mechanism

NCBI chr 1:25,674,751...25,693,684
Ensembl chr 1:26,739,268...26,758,028

G

neuronal acetylcholine receptor subunit alpha-7

CTD Direct Evidence: marker/mechanism

NCBI chr15:10,525,535...10,667,227
Ensembl chr15:29,565,885...29,705,194

G

metallothionein-2

CTD Direct Evidence: marker/mechanism

NCBI chr16:36,894,853...36,895,826
Ensembl chr16:56,007,922...56,028,093

G

lysyl oxidase like 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:22,547,303...22,653,676
Ensembl chr 8:19,483,335...19,589,522

G

mitogen-activated protein kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr22:3,883,119...3,990,368
Ensembl chr22:20,365,487...20,450,335

G

mitogen-activated protein kinase 3

CTD Direct Evidence: marker/mechanism

Ensembl chr16:30,489,362...30,498,017

G

MET proto-oncogene, receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 7:108,646,278...108,772,238
Ensembl chr 7:121,365,438...121,468,159

G

matrix metallopeptidase 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:97,730,545...97,739,190
Ensembl chr11:101,221,393...101,230,104

G

matrix metallopeptidase 14

CTD Direct Evidence: marker/mechanism

NCBI chr14:3,654,125...3,665,158
Ensembl chr14:21,753,305...21,764,058

G

matrix metallopeptidase 2

CTD Direct Evidence: marker/mechanism

PMID:18398872 PMID:19770485 PMID:22321834 PMID:23707804 PMID:34278709

NCBI chr16:35,711,866...35,738,881
Ensembl chr16:54,812,694...54,844,279

G

matrix metallopeptidase 3

CTD Direct Evidence: marker/mechanism

PMID:20188714 PMID:26284488

NCBI chr11:97,776,729...97,784,549
Ensembl chr11:101,267,566...101,275,354

G

matrix metallopeptidase 9

CTD Direct Evidence: marker/mechanism

PMID:19617202 PMID:19700239 PMID:20188714 PMID:21187089 PMID:22503731 More...

NCBI chr20:42,346,305...42,354,018
Ensembl chr20:43,432,389...43,440,129

G

metallothionein 3

CTD Direct Evidence: marker/mechanism

NCBI chr16:36,875,919...36,877,558
Ensembl chr16:56,007,922...56,028,093

G

metadherin

CTD Direct Evidence: marker/mechanism

NCBI chr 8:94,282,432...94,368,516
Ensembl chr 8:96,473,247...96,551,341

G

MYD88 innate immune signal transduction adaptor

CTD Direct Evidence: marker/mechanism

NCBI chr 3:38,036,565...38,041,014
Ensembl chr 3:38,319,024...38,323,572

G

myosin heavy chain 9

CTD Direct Evidence: marker/mechanism

NCBI chr22:17,200,623...17,305,826
Ensembl chr22:35,039,101...35,121,618

G

myosin light chain kinase

CTD Direct Evidence: marker/mechanism

PMID:10232591 PMID:12970723

NCBI chr 3:120,711,705...120,983,432
Ensembl chr 3:127,614,173...127,793,261

G

neural cell adhesion molecule 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:107,845,507...108,160,441
Ensembl chr11:111,925,677...112,000,401

G

NIMA related kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:187,225,947...187,243,605
Ensembl chr 1:192,092,885...192,105,737

G

NFE2 like bZIP transcription factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr2B:64,509,446...64,544,600
Ensembl chr2B:182,214,116...182,248,085

G

NME/NM23 nucleoside diphosphate kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:45,243,588...45,252,135
Ensembl chr17:50,113,622...50,131,636

G

notch receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:82,457,829...82,615,142
Ensembl chr 1:117,538,243...117,612,840

G

neuregulin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:30,954,852...32,084,411
Ensembl chr 8:29,050,222...29,263,977

G

NUAK family kinase 1

CTD Direct Evidence: marker/mechanism

PMID:26213588 PMID:26873845

NCBI chr12:103,642,744...103,720,352
Ensembl chr12:107,037,627...107,113,163

G

PAGE family member 4

CTD Direct Evidence: marker/mechanism

NCBI chr X:42,044,199...42,048,954
Ensembl chr X:49,758,858...49,763,611

G

p21 (RAC1) activated kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:72,372,577...72,524,817
Ensembl chr11:76,015,998...76,104,197

G

paired box 6

CTD Direct Evidence: marker/mechanism

NCBI chr11:31,753,190...31,782,225
Ensembl chr11:31,641,813...31,664,474

G

programmed cell death 4

CTD Direct Evidence: marker/mechanism

NCBI chr10:107,465,084...107,493,285
Ensembl chr10:110,914,222...110,942,394

G

phosphatidylinositol-4-phosphate 5-kinase type 1 alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 1:126,547,793...126,598,618
Ensembl chr 1:130,195,974...130,246,198

G

pyruvate kinase M1/2

CTD Direct Evidence: marker/mechanism

PMID:15048980 PMID:15654357

NCBI chr15:51,149,584...51,182,193
Ensembl chr15:69,913,455...69,945,832

G

plasminogen activator, urokinase

CTD Direct Evidence: marker/mechanism

PMID:14644129 PMID:26284488

NCBI chr10:70,433,340...70,441,569
Ensembl chr10:73,105,895...73,113,136

G

plasminogen activator, urokinase receptor

CTD Direct Evidence: marker/mechanism

NCBI chr19:40,588,100...40,616,479
Ensembl chr19:49,197,341...49,222,561
Ensembl chr19:49,197,341...49,222,561

G

protein phosphatase 1 regulatory subunit 12B

CTD Direct Evidence: marker/mechanism

NCBI chr 1:177,945,674...178,185,871
Ensembl chr 1:182,243,497...182,482,216

G

peroxiredoxin 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:12,359,084...12,363,552
Ensembl chr19:13,103,422...13,107,369

G

phosphatase and tensin homolog

CTD Direct Evidence: therapeutic

NCBI chr10:84,587,841...84,689,043
Ensembl chr10:88,093,539...88,194,605

G

protein tyrosine kinase 2

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:12811834 PMID:25199511

NCBI chr 8:137,330,777...137,677,306
Ensembl chr 8:140,412,773...140,684,898

G

RAB27A, member RAS oncogene family

CTD Direct Evidence: marker/mechanism

NCBI chr15:34,174,491...34,263,045
Ensembl chr15:52,498,202...52,529,984

G

RAB27B, member RAS oncogene family

CTD Direct Evidence: marker/mechanism

NCBI chr18:48,099,912...48,274,416
Ensembl chr18:51,542,842...51,604,061

G

RAS protein activator like 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:153,609,277...153,986,155
Ensembl chr 1:157,303,646...157,670,415

G

RNA binding motif protein 38

CTD Direct Evidence: therapeutic

NCBI chr20:53,731,641...53,749,688

G

reversion inducing cysteine rich protein with kazal motifs

CTD Direct Evidence: therapeutic

NCBI chr 9:35,886,741...35,974,133
Ensembl chr 9:36,699,631...36,774,116

G

RELA proto-oncogene, NF-kB subunit

CTD Direct Evidence: marker/mechanism

PMID:19896475 PMID:29501572

NCBI chr11:61,012,839...61,022,225
Ensembl chr11:64,347,859...64,356,868

G

ras homolog family member A

CTD Direct Evidence: marker/mechanism

NCBI chr 3:49,282,009...49,339,887

G

ring finger protein 207

CTD Direct Evidence: marker/mechanism

NCBI chr 1:4,972,787...4,986,992
Ensembl chr 1:6,229,241...6,242,770

G

ribosomal protein L3 like

CTD Direct Evidence: marker/mechanism

NCBI chr16:749,186...760,331
Ensembl chr16:2,033,466...2,043,719

G

ribosomal protein S6 kinase A3

CTD Direct Evidence: marker/mechanism

NCBI chr X:12,772,368...12,893,062
Ensembl chr X:20,133,898...20,251,244

G

ribosomal protein SA

CTD Direct Evidence: marker/mechanism

NCBI chr 3:39,311,321...39,317,083
Ensembl chr 3:39,591,012...39,596,748

G

S100 calcium binding protein A11

CTD Direct Evidence: marker/mechanism

NCBI chr 1:127,391,695...127,396,231
Ensembl chr 1:131,034,588...131,035,882

G

S100 calcium binding protein A4

CTD Direct Evidence: marker/mechanism

NCBI chr 1:128,898,765...128,901,042
Ensembl chr 1:132,527,846...132,530,122

G

sphingosine-1-phosphate receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:9,771,888...9,781,944
Ensembl chr19:10,436,502...10,437,563

G

septin 9

CTD Direct Evidence: marker/mechanism

NCBI chr17:71,361,002...71,580,995
Ensembl chr17:76,920,236...77,139,586

G

SET nuclear proto-oncogene

CTD Direct Evidence: marker/mechanism

NCBI chr 9:99,806,876...99,819,825
Ensembl chr 9:128,473,806...128,484,563

G

solute carrier family 39 member 10

CTD Direct Evidence: marker/mechanism

NCBI chr2B:82,823,472...82,981,894
Ensembl chr2B:200,805,459...200,883,524

G

solute carrier family 6 member 12

CTD Direct Evidence: marker/mechanism

NCBI chr12:247,905...274,518
Ensembl chr12:224,566...249,202

G

sphingomyelin phosphodiesterase 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:6,521,812...6,526,349

G

snail family transcriptional repressor 1

CTD Direct Evidence: marker/mechanism

PMID:22580338 PMID:24014025

NCBI chr20:46,321,075...46,328,865
Ensembl chr20:47,384,818...47,390,733

G

snail family transcriptional repressor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:45,341,857...45,345,544
Ensembl chr 8:42,723,971...42,730,904

G

superoxide dismutase 2

CTD Direct Evidence: marker/mechanism

PMID:10853026 PMID:11053990 PMID:15048980 PMID:15654357 PMID:21749277 More...

NCBI chr 6:157,562,814...157,610,155
Ensembl chr 6:162,576,082...162,589,960

G

sortilin related receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:116,297,014...116,477,399
Ensembl chr11:120,222,491...120,402,432

G

SRY-box transcription factor 11

CTD Direct Evidence: marker/mechanism

NCBI chr2A:5,699,738...5,711,210

G

SRY-box transcription factor 9

CTD Direct Evidence: marker/mechanism

NCBI chr17:66,028,737...66,034,122

G

Sp1 transcription factor

CTD Direct Evidence: marker/mechanism

PMID:26317792 PMID:35072892

NCBI chr12:35,338,492...35,374,462
Ensembl chr12:36,127,681...36,158,356

G

SRC proto-oncogene, non-receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

PMID:18844224 PMID:21291860

NCBI chr20:33,667,614...33,727,126
Ensembl chr20:34,822,271...34,839,634

G

signal transducer and activator of transcription 3

CTD Direct Evidence: marker/mechanism

NCBI chr17:14,928,689...15,003,644
Ensembl chr17:15,152,358...15,227,067

G

small ubiquitin like modifier 1

CTD Direct Evidence: marker/mechanism

NCBI chr2B:89,461,773...89,493,879
Ensembl chr2B:207,613,654...207,645,590

G

T-box transcription factor 15

CTD Direct Evidence: marker/mechanism

NCBI chr 1:83,556,763...83,663,453
Ensembl chr 1:118,553,638...118,659,379

G

transferrin

CTD Direct Evidence: marker/mechanism

NCBI chr 3:130,799,063...130,830,227
Ensembl chr 3:138,274,159...138,305,476

G

tissue factor pathway inhibitor 2

NCBI chr 7:85,835,141...85,839,515
Ensembl chr 7:99,426,006...99,431,099

G

transforming growth factor beta 1

CTD Direct Evidence: marker/mechanism

PMID:23992306 PMID:24727557 PMID:24793912 PMID:25884904 PMID:26896736 More...

NCBI chr19:38,324,009...38,347,003
Ensembl chr19:46,831,659...46,852,973

G

TGFB induced factor homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr18:10,819,015...10,830,282
Ensembl chr18:13,128,359...13,139,145

G

TIMP metallopeptidase inhibitor 1

CTD Direct Evidence: therapeutic

NCBI chr X:40,018,190...40,022,636
Ensembl chr X:47,914,906...47,919,419

G

TIMP metallopeptidase inhibitor 3

CTD Direct Evidence: therapeutic

NCBI chr22:13,811,297...13,872,799
Ensembl chr22:31,662,562...31,723,964

G

transketolase

CTD Direct Evidence: marker/mechanism

NCBI chr 3:53,168,426...53,199,003
Ensembl chr 3:54,389,549...54,420,704

G

talin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:35,549,328...35,583,376
Ensembl chr 9:36,351,836...36,379,228

G

toll like receptor 4

CTD Direct Evidence: marker/mechanism

NCBI chr 9:88,827,495...88,840,458
Ensembl chr 9:117,180,550...117,190,711

G

transmembrane protein 139

CTD Direct Evidence: marker/mechanism

Ensembl chr 7:147,770,478...147,773,583

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

PMID:22199285 PMID:23431386 PMID:23899529 PMID:24613819

NCBI chr 6:31,236,650...31,239,423
Ensembl chr 6:32,126,618...32,129,381

G

tumor protein p53 binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:199,403,194...199,469,079
Ensembl chr 1:204,414,218...204,457,739

G

tripartite motif containing 47

CTD Direct Evidence: marker/mechanism

NCBI chr17:69,824,959...69,829,442
Ensembl chr17:75,376,071...75,379,964

G

transient receptor potential cation channel subfamily M member 7

CTD Direct Evidence: marker/mechanism

NCBI chr15:29,513,220...29,639,506
Ensembl chr15:47,853,187...47,977,451

G

twist family bHLH transcription factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:19,761,041...19,765,665

G

thioredoxin

CTD Direct Evidence: marker/mechanism

NCBI chr 9:81,399,056...81,411,607
Ensembl chr 9:109,565,557...109,578,311

G

ubiquilin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:41,170,416...41,218,656
Ensembl chr 9:82,597,507...82,645,587

G

vimentin

CTD Direct Evidence: marker/mechanism

NCBI chr10:17,546,389...17,554,702
Ensembl chr10:17,818,285...17,826,642

G

XPC complex subunit, DNA damage recognition and repair factor

CTD Direct Evidence: marker/mechanism

NCBI chr 3:14,063,499...14,097,023
Ensembl chr 3:14,403,958...14,437,377

G

X-ray repair cross complementing 3

CTD Direct Evidence: marker/mechanism

NCBI chr14:84,323,644...84,341,763
Ensembl chr14:104,131,903...104,149,037

G

Yes1 associated transcriptional regulator

CTD Direct Evidence: marker/mechanism

NCBI chr11:97,061,367...97,186,961
Ensembl chr11:100,552,424...100,681,301

G

zinc finger and BTB domain containing 16

CTD Direct Evidence: marker/mechanism

NCBI chr11:108,938,414...109,133,819
Ensembl chr11:112,780,380...112,977,164

G

zinc finger E-box binding homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:31,449,202...31,659,534
Ensembl chr10:32,046,491...32,253,550

G

zinc finger E-box binding homeobox 2

CTD Direct Evidence: marker/mechanism

NCBI chr2B:15,325,094...15,460,908
Ensembl chr2B:148,460,904...148,596,500

G

ZFP36 ring finger protein

CTD Direct Evidence: therapeutic

NCBI chr19:36,505,056...36,507,693
Ensembl chr19:45,052,801...45,055,390

G

zinc finger RNA binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr 5:77,890,015...77,980,332
Ensembl chr 5:83,295,040...83,361,615

G

zinc finger protein 367

CTD Direct Evidence: marker/mechanism

NCBI chr 9:67,483,257...67,515,630
Ensembl chr 9:95,608,140...95,638,326

Neoplasm Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:79,497,536...79,706,277
Ensembl chr 7:93,147,950...93,243,238

G

ATP binding cassette subfamily C member 4 (PEL blood group)

CTD Direct Evidence: marker/mechanism

NCBI chr13:76,193,929...76,476,119
Ensembl chr13:95,349,915...95,582,058

G

angiotensin I converting enzyme

CTD Direct Evidence: marker/mechanism

NCBI chr17:57,556,294...57,577,294
Ensembl chr17:62,702,341...62,733,853

G

atypical chemokine receptor 3

CTD Direct Evidence: marker/mechanism

NCBI chr2B:123,795,664...123,810,067
Ensembl chr2B:242,666,173...242,667,261

G

acyl-CoA synthetase bubblegum family member 1

associated with pheochromocytoma

NCBI chr15:57,098,752...57,164,119
Ensembl chr15:76,064,937...76,128,835

G

activin A receptor type 2A

exacerbates

associated with colon cancer;mRNA,protein:decreased expression:colon (human)

NCBI chr2B:11,933,683...12,020,287
Ensembl chr2B:152,253,826...152,288,385

G

adhesion G protein-coupled receptor B1

associated with colorectal cancer

NCBI chr 8:139,154,065...139,251,115
Ensembl chr 8:142,220,827...142,301,070

G

adenosine A2b receptor

CTD Direct Evidence: marker/mechanism

NCBI chr17:34,849,466...34,880,088

G

angiotensin II receptor type 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:145,722,475...145,767,550
Ensembl chr 3:153,341,947...153,345,380

G

angiotensin II receptor type 2

CTD Direct Evidence: marker/mechanism

NCBI chr X:105,252,903...105,257,171
Ensembl chr X:115,671,594...115,672,685

G

aryl hydrocarbon receptor

CTD Direct Evidence: therapeutic

NCBI chr 7:17,949,254...17,998,737
Ensembl chr 7:17,278,637...17,326,171

G

akirin 2

NCBI chr 6:85,549,728...85,577,114

G

AKT serine/threonine kinase 2

associated with Mammary Neoplasms, Experimental

NCBI chr19:37,275,799...37,331,971
Ensembl chr19:45,791,800...45,840,271

G

aldolase, fructose-bisphosphate A

CTD Direct Evidence: marker/mechanism

G

ALK receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

PMID:22986231 PMID:22999080

NCBI chr2A:29,196,195...29,930,062
Ensembl chr2A:29,276,041...30,006,735

G

arachidonate 5-lipoxygenase

CTD Direct Evidence: marker/mechanism

NCBI chr10:42,461,398...42,531,576
Ensembl chr10:45,639,946...45,710,016

G

adhesion molecule with Ig like domain 2

Liver Metastasis

NCBI chr12:41,652,954...41,656,393
Ensembl chr12:42,525,858...42,527,426

G

angiopoietin like 4

CTD Direct Evidence: therapeutic

NCBI chr19:7,649,429...7,660,154
Ensembl chr19:8,499,858...8,510,148

G

ANTXR cell adhesion molecule 1

associated with Mammary Neoplasms, Experimental;

NCBI chr2A:69,054,253...69,290,554
Ensembl chr2A:70,175,982...70,412,454

G

annexin A1

treatment

associated with Mammary Neoplasms, Experimental
CTD Direct Evidence: marker/mechanism
associated with Mammary Neoplasms, Experimental;protein:increased expression:lung

PMID:9514092 PMID:20308542 PMID:20821804

RGD:2306939 RGD:7421541 RGD:7421563

NCBI chr 9:51,647,404...51,665,990
Ensembl chr 9:71,929,728...71,948,779

G

annexin A4

CTD Direct Evidence: marker/mechanism

NCBI chr2A:69,686,651...69,869,340
Ensembl chr2A:70,902,260...70,986,917

G

annexin A7

associated with Breast Neoplasms;protein:increased expression:breast
associated with Prostatic Neoplasms;protein:decreased expression:prostate gland

PMID:11287641 PMID:15073110

RGD:2292655 RGD:2292656

NCBI chr10:69,923,353...69,962,980
Ensembl chr10:72,381,447...72,420,749

G

apolipoprotein E

NCBI chr19:41,853,669...41,857,252
Ensembl chr19:50,459,906...50,463,490

G

Rho GDP dissociation inhibitor alpha

CTD Direct Evidence: marker/mechanism

NCBI chr17:76,273,196...76,276,942
Ensembl chr17:81,975,340...81,978,447

G

AT-rich interaction domain 1A

disease_progression

in lung; associated with hepatocellular carcinoma

NCBI chr 1:25,960,868...26,047,057
Ensembl chr 1:27,018,616...27,103,239

G

ATPase H+ transporting V1 subunit C1

associated with Mammary Neoplasms, Experimental

NCBI chr 8:99,521,146...99,725,603
Ensembl chr 8:101,832,538...101,883,956

G

AXL receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr19:38,211,555...38,254,464
Ensembl chr19:46,719,615...46,761,747

G

antizyme inhibitor 1

associated with colorectal cancer;RNA:increased editing:colorectum
associated with stomach cancer;RNA:increased editing:stomach

PMID:29925690 PMID:30563560

RGD:14700703 RGD:14700704

NCBI chr 8:99,483,027...99,521,151
Ensembl chr 8:101,639,950...101,678,604

G

BCL2 associated X, apoptosis regulator

associated with Carcinoma, Infiltrating Duct

NCBI chr19:45,955,926...45,962,870
Ensembl chr19:54,793,594...54,800,468

G

BCL2 apoptosis regulator

associated with Breast Neoplasms
associated with Carcinoma, Renal Cell

PMID:12810203 PMID:16826579

RGD:2293020 RGD:2293021

NCBI chr18:56,481,212...56,679,012
Ensembl chr18:59,802,443...59,992,100

G

bone morphogenetic protein 6

severity

associated with Prostatic Neoplasms;protein:increased expression:bone

NCBI chr 6:7,564,164...7,720,341
Ensembl chr 6:7,848,249...8,000,649

G

bone morphogenetic protein 7

disease_progression

associated with Prostatic Neoplasms;mRNA:increased expression:bone
associated with Breast Neoplasms;protein:increased expression:breast

PMID:12539225 PMID:17895257

RGD:2289029 RGD:2289033

NCBI chr20:53,509,484...53,606,889
Ensembl chr20:54,788,974...54,885,021

G

B-Raf proto-oncogene, serine/threonine kinase

onset

associated with Melanoma; DNA:mutations: :

NCBI chr 7:132,651,908...132,855,422
Ensembl chr 7:145,138,510...145,327,115

G

bromodomain containing 4

NCBI chr19:14,768,239...14,805,770
Ensembl chr19:15,754,930...15,789,600

G

BRMS1 transcriptional repressor and anoikis regulator

CTD Direct Evidence: therapeutic

NCBI chr11:61,703,021...61,710,784
Ensembl chr11:65,028,407...65,036,163

G

basigin (Ok blood group)

CTD Direct Evidence: marker/mechanism

Ensembl chr19:539,815...551,456

G

calcium binding protein 39

associated with hepatocellular carcinoma;

NCBI chr2B:117,965,688...118,074,063
Ensembl chr2B:236,809,549...236,870,646

G

calcyclin binding protein

associated with pancreatic neoplasms

NCBI chr 1:150,511,021...150,522,369
Ensembl chr 1:154,210,001...154,220,583

G

calmodulin like 3

ameliorates

associated with hepatocellular carcinoma; human cells in mouse model
associated with hepatocellular carcinoma; protein:decreased expression:liver (human)

NCBI chr10:5,565,223...5,567,471
Ensembl chr10:5,551,906...5,552,355

G

cyclase associated actin cytoskeleton regulatory protein 1

associated with Pancreatic Neoplasms; mRNA, protein:increased expression:pancreas

NCBI chr 1:39,325,715...39,358,365
Ensembl chr 1:40,651,262...40,683,777

G

caspase 3

associated with Breast Neoplasms

NCBI chr 4:176,793,190...176,815,023
Ensembl chr 4:189,018,422...189,040,185

G

catalase

CTD Direct Evidence: therapeutic

PMID:12538496 PMID:22580338 PMID:23518002

NCBI chr11:34,413,253...34,446,831
Ensembl chr11:34,289,603...34,323,160

G

caveolin 1

treatment

CTD Direct Evidence: marker/mechanism
associated with Mammary Neoplasms, Experimental

PMID:15334058 PMID:15355971 PMID:20562527

RGD:2289106 RGD:8661780

NCBI chr 7:108,497,125...108,533,090
Ensembl chr 7:121,193,424...121,229,655

G

chromobox 4

associated with Carcinoma, Hepatocellular;

NCBI chr17:73,913,264...73,919,540
Ensembl chr17:79,449,919...79,458,866

G

chromobox 5

associated with Lung Neoplasms;

NCBI chr12:34,463,826...34,521,656
Ensembl chr12:35,218,239...35,236,009

G

C-C motif chemokine ligand 2

associated with Mammary Neoplasms, Experimental

NCBI chr17:22,528,154...22,530,091
Ensembl chr17:22,820,890...22,823,384

G

C-C motif chemokine ligand 20

CTD Direct Evidence: marker/mechanism

NCBI chr2B:115,052,768...115,056,479
Ensembl chr2B:233,862,505...233,866,225

G

C-C motif chemokine ligand 5

treatment

associated with Animal Mammary Neoplasms;

NCBI chr17:20,915,198...20,923,530
Ensembl chr17:21,210,798...21,219,172

G

cellular communication network factor 4

CTD Direct Evidence: marker/mechanism

NCBI chr 8:129,842,580...129,884,528
Ensembl chr 8:132,818,397...132,858,861

G

cyclin A2

associated with Seminoma;protein:increased expression:testis

NCBI chr 4:114,016,917...114,024,816
Ensembl chr 4:125,153,810...125,161,302

G

cyclin D1

treatment

associated with Carcinoma, Non-Small-Cell Lung;mRNA:splice variant
associated with stomach cancer; human cells in mouse model

PMID:18715616 PMID:27431311

RGD:13434926 RGD:152995400

NCBI chr11:64,737,006...64,750,353

G

cyclin D2

associated with Breast Neoplasms;DNA:hypermethylated:brain

NCBI chr12:4,385,957...4,417,602
Ensembl chr12:4,309,272...4,335,551

G

cyclin E1

disease_progression

protein:altered processing
associated with non-small cell lung carcinoma

PMID:11212263 PMID:17671189

RGD:13673913 RGD:2289229

NCBI chr19:26,739,285...26,751,630
Ensembl chr19:35,496,700...35,510,295

G

C-C motif chemokine receptor 5

CTD Direct Evidence: marker/mechanism

NCBI chr 3:46,273,096...46,278,471
Ensembl chr 3:47,380,321...47,381,379

G

CD274 molecule

disease_progression

associated with ovarian cancer

NCBI chr 9:5,269,270...5,289,629
Ensembl chr 9:5,454,391...5,474,402

G

CD44 molecule (IN blood group)

associated with Carcinoma, Renal Cell;protein:increased expression:kidney
CTD Direct Evidence: marker/mechanism

PMID:18026989 PMID:23098472

NCBI chr11:35,110,732...35,258,238
Ensembl chr11:34,985,634...35,079,009

G

CD82 molecule

associated with Prostatic Neoplasms;mRNA:decreased expression:bone
CTD Direct Evidence: therapeutic
associated with Prostatic Neoplasms;DNA:loss of heterozygosity
associated with Carcinoma, Hepatocellular;mRNA:decreased expression
associated with Carcinoma, Infiltrating Duct;mRNA:decreased expression:brain

PMID:9254900 PMID:9831222 PMID:11275982 PMID:12806379 PMID:15592684 More...

RGD:2289400 RGD:2289402 RGD:2289407 RGD:2289425 RGD:68869

NCBI chr11:44,526,010...44,581,560
Ensembl chr11:45,020,319...45,075,876

G

CD86 molecule

mRNA:decreased expression:mediastinal lymph node (rat)

NCBI chr 3:119,151,884...119,217,641
Ensembl chr 3:126,059,008...126,124,339

G

cadherin 1

treatment

associated with Prostatic Neoplasms
associated with stomach cancer; human cells in mouse model
CTD Direct Evidence: marker/mechanism

PMID:17520682 PMID:18008331 PMID:22580338 PMID:27431311

RGD:152995400 RGD:2289488

NCBI chr16:49,108,745...49,206,347
Ensembl chr16:68,502,584...68,596,488

G

cadherin 2

CTD Direct Evidence: marker/mechanism

NCBI chr18:21,210,001...21,435,919
Ensembl chr18:24,812,019...25,008,325

G

cyclin dependent kinase like 2

CTD Direct Evidence: marker/mechanism

NCBI chr 4:48,575,933...48,628,916
Ensembl chr 4:54,415,305...54,458,111

G

cyclin dependent kinase inhibitor 1A

associated with Melanoma;

NCBI chr 6:36,241,405...36,250,032
Ensembl chr 6:37,436,990...37,445,599

G

cyclin dependent kinase inhibitor 2A

associated with Paraganglioma, Extra-Adrenal;DNA:hypermethylation

NCBI chr 9:21,803,862...21,831,322

G

cofilin 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:61,215,092...61,218,628
Ensembl chr11:64,544,275...64,550,806

G

glycoprotein hormones, alpha polypeptide

associated with Breast Neoplasms;protein:increased expression:serum

NCBI chr 6:84,962,974...84,972,638
Ensembl chr 6:88,236,206...88,247,300

G

checkpoint kinase 1

associated with Pancreatic Neoplasms

NCBI chr11:120,446,352...120,478,207
Ensembl chr11:124,359,218...124,390,981

G

component of inhibitor of nuclear factor kappa B kinase complex

associated with prostate adenocarcinoma

NCBI chr10:96,794,228...96,835,449
Ensembl chr10:100,280,490...100,316,918

G

capicua transcriptional repressor

CTD Direct Evidence: marker/mechanism

NCBI chr19:39,156,204...39,183,498
Ensembl chr19:47,751,520...47,774,699

G

claudin 7

NCBI chr17:7,289,766...7,292,433
Ensembl chr17:7,277,313...7,281,859

G

chloride intracellular channel 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:31,391,958...31,397,920
Ensembl chr 6:32,280,645...32,286,621

G

clusterin

associated with Breast Neoplasms

NCBI chr 8:26,867,973...26,884,838
Ensembl chr 8:24,070,053...24,083,523

G

cAMP responsive element binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr2B:94,762,796...94,836,304
Ensembl chr2B:212,891,261...212,958,130

G

colony stimulating factor 1

associated with Prostatic Neoplasms

NCBI chr 1:112,555,755...112,575,894
Ensembl chr 1:127,764,916...127,781,943

G

colony stimulating factor 1 receptor

exacerbates

CTD Direct Evidence: marker/mechanism
associated with breast cancer
associated with Prostatic Neoplasms

PMID:1390197 PMID:18510570 PMID:25005824

RGD:150524287 RGD:2293638

NCBI chr 5:145,478,725...145,537,858
Ensembl chr 5:151,483,572...151,517,415

G

colony stimulating factor 3

CTD Direct Evidence: therapeutic

PMID:7543699 PMID:9018096

NCBI chr17:17,271,074...17,273,493
Ensembl chr17:17,491,276...17,493,729

G

cystatin C

protein:decreased expression:cerebrospinal fluid

NCBI chr20:23,583,043...23,587,399
Ensembl chr20:23,935,942...23,940,425

G

cystatin A

CTD Direct Evidence: marker/mechanism

NCBI chr 3:119,417,489...119,432,244
Ensembl chr 3:126,323,901...126,338,430

G

cytotoxic T-lymphocyte associated protein 4

disease_progression

associated with Mammary Neoplasms, Experimental

PMID:15701862 PMID:18049334

RGD:4891518 RGD:7204722

NCBI chr2B:91,054,917...91,106,234
Ensembl chr2B:209,239,417...209,244,498

G

catenin beta 1

associated with Prostatic Neoplasms
CTD Direct Evidence: marker/mechanism

PMID:18008331 PMID:29106415

NCBI chr 3:41,104,940...41,145,934
Ensembl chr 3:41,373,726...41,414,030

G

cathepsin B

protein:increased expression:cerebrospinal fluid

NCBI chr 8:7,333,498...7,359,264

G

cathepsin D

protein:increased expression:oral cavity, oropharynx, hypopharynx (human)

NCBI chr11:1,789,326...1,800,524

G

cathepsin H

protein:increased expression:cerebrospinal fluid

NCBI chr15:57,893,379...57,917,194
Ensembl chr15:76,852,668...76,876,976

G

cytosolic thiouridylase subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:48,065,741...48,075,758

G

cytosolic thiouridylase subunit 2

CTD Direct Evidence: marker/mechanism

NCBI chr16:69,419,811...69,428,500
Ensembl chr16:89,079,132...89,088,231

G

C-X3-C motif chemokine receptor 1

susceptibility

associated with Breast Neoplasms

NCBI chr 3:39,158,346...39,176,604
Ensembl chr 3:39,440,955...39,457,219

G

C-X-C motif chemokine ligand 12

treatment

associated with Pancreatic Carcinoma
CTD Direct Evidence: marker/mechanism
associated with Pancreatic Neoplasms

PMID:12761880 PMID:21312072 PMID:23743303 PMID:26330165

RGD:10398726 RGD:2317610

NCBI chr10:41,296,975...41,384,864
Ensembl chr10:44,552,480...44,564,231

G

C-X-C motif chemokine receptor 3

associated with Mammary Neoplasms, Experimental

NCBI chr X:60,880,759...60,883,355
Ensembl chr X:70,933,160...70,935,756

G

C-X-C motif chemokine receptor 4

ameliorates
severity
disease_progression

CTD Direct Evidence: marker/mechanism
associated with lung non-small cell carcinoma; protein:increased expression:lung (human)
associated with Otorhinolaryngologic Neoplasms;mRNA,protein:increased expression:Laryngeal and hypopharyngeal tissue (human)
associated with lung non-small cell carcinoma;mRNA,protein:increased expression:lung (human)
associated with oral squamous cell carcinoma
associated with pancreatic cancer
associated with osteosarcoma;protein:increased expression:bone (human)
associated with lung cancer; human cells in mouse model
human cells in mouse model;associated with lung cancer

PMID:16230077 PMID:16322285 PMID:17634424 PMID:18487224 PMID:21312072 More...

RGD:151708730 RGD:152023741 RGD:152023745 RGD:152023746 RGD:152025556 RGD:152177475 RGD:152177476 RGD:152177478 RGD:152177479

NCBI chr2B:23,744,271...23,748,106
Ensembl chr2B:140,181,829...140,189,647

G

cytochrome P450 family 19 subfamily A member 1

CTD Direct Evidence: marker/mechanism

NCBI chr15:30,152,924...30,282,854
Ensembl chr15:48,486,688...48,521,554

G

DAB2 interacting protein

severity

associated with colorectal cancer;protein:decreased expression:colorectum (human)

NCBI chr 9:92,696,798...92,912,425
Ensembl chr 9:121,143,457...121,254,336

G

death associated protein kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:58,628,872...58,836,205
Ensembl chr 9:86,681,953...86,887,958

G

death domain associated protein

NCBI chr 6:32,890,846...32,895,307
Ensembl chr 6:34,004,543...34,008,717

G

decorin

associated with Breast Neoplasms

NCBI chr12:88,678,791...88,715,677
Ensembl chr12:91,994,129...92,031,413

G

discoidin domain receptor tyrosine kinase 1

severity

protein:increased expression:bone (human)
mRNA:increased expression:ovary (human)

PMID:28743276 PMID:29039472

RGD:151347541 RGD:151347601

NCBI chr 6:30,625,871...30,645,066
Ensembl chr 6:31,496,047...31,513,455

G

discoidin domain receptor tyrosine kinase 2

ameliorates

associated with melanoma;

NCBI chr 1:138,048,730...138,200,426
Ensembl chr 1:141,932,158...141,990,766

G

DEAD-box helicase 3 X-linked

human cells in mouse model

NCBI chr X:33,780,381...33,796,829
Ensembl chr X:41,475,116...41,505,837

G

DEK proto-oncogene

CTD Direct Evidence: marker/mechanism

NCBI chr 6:18,071,928...18,112,245
Ensembl chr 6:18,427,844...18,465,606

G

dihydrofolate reductase

disease_progression

CTD Direct Evidence: marker/mechanism

PMID:8149482 PMID:19159907

NCBI chr 5:34,663,210...34,689,467
Ensembl chr 5:34,938,548...34,967,003

G

iodothyronine deiodinase 3

CTD Direct Evidence: marker/mechanism

NCBI chr14:82,188,126...82,190,220

G

dystrophin

CTD Direct Evidence: marker/mechanism

NCBI chr X:23,728,650...26,338,849
Ensembl chr X:31,282,415...33,492,733

G

DNA methyltransferase 3 beta

associated with Uterine Cervical Neoplasms;

NCBI chr20:29,049,993...29,096,957
Ensembl chr20:30,186,069...30,215,487

G

dihydropyrimidine dehydrogenase

treatment

CTD Direct Evidence: marker/mechanism
associated with Colonic Neoplasms

PMID:11383214 PMID:17611699

NCBI chr 1:99,736,145...100,576,663
Ensembl chr 1:98,457,934...99,300,100

G

E2F transcription factor 1

severity

protein:increased expression:bone (human)

NCBI chr20:29,963,083...29,973,860
Ensembl chr20:31,103,764...31,110,604

G

E2F transcription factor 8

CTD Direct Evidence: marker/mechanism

NCBI chr11:19,250,045...19,267,629
Ensembl chr11:19,162,837...19,179,744

G

endothelin 1

NCBI chr 6:12,076,312...12,142,861
Ensembl chr 6:12,462,718...12,503,545

G

endothelin receptor type A

associated with Bladder Neoplasms

NCBI chr 4:139,815,336...139,879,600
Ensembl chr 4:151,476,356...151,536,497

G

eukaryotic translation elongation factor 1 beta 2

CTD Direct Evidence: marker/mechanism

PMID:17085005 PMID:20562527

NCBI chr2B:93,399,413...93,402,779
Ensembl chr2B:211,528,497...211,531,826

G

eukaryotic translation elongation factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:3,000,608...3,009,918
Ensembl chr19:3,950,772...3,960,172

G

ephrin B2

associated with cholangiocarcinoma;protein:increased expression:biliary ductule (human)

NCBI chr13:87,629,831...87,675,652
Ensembl chr13:106,770,296...106,815,548

G

epidermal growth factor

CTD Direct Evidence: marker/mechanism

PMID:21942447 PMID:23064031

NCBI chr 4:102,410,724...102,509,691
Ensembl chr 4:112,977,565...113,076,460

G

epidermal growth factor receptor

CTD Direct Evidence: marker/mechanism

PMID:17369752 PMID:17575224 PMID:23867902

NCBI chr 7:55,614,042...55,807,285
Ensembl chr 7:56,046,296...56,111,615

G

euchromatic histone lysine methyltransferase 2

associated with lung neoplasms;
CTD Direct Evidence: marker/mechanism

PMID:20940408 PMID:25115793

NCBI chr 6:31,542,946...31,560,894
Ensembl chr 6:32,429,271...32,451,844

G

eukaryotic translation initiation factor 1A X-linked

CTD Direct Evidence: marker/mechanism

NCBI chr X:12,743,907...12,764,313
Ensembl chr X:20,103,872...20,123,464

G

eukaryotic translation initiation factor 4A2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:183,818,449...183,824,870
Ensembl chr 3:192,284,037...192,290,644

G

elongator acetyltransferase complex subunit 3

CTD Direct Evidence: marker/mechanism

NCBI chr 8:27,370,360...27,470,169
Ensembl chr 8:24,570,410...24,669,941

G

EMAP like 4

CTD Direct Evidence: marker/mechanism

PMID:22986231 PMID:22999080

NCBI chr2A:42,267,435...42,430,231
Ensembl chr2A:43,119,984...43,281,825

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:116,248,587...116,364,966
Ensembl chr 8:118,998,530...119,114,273

G

epithelial cell adhesion molecule

NCBI chr2A:47,490,748...47,508,418
Ensembl chr2A:48,413,520...48,432,038

G

erythropoietin

CTD Direct Evidence: marker/mechanism

NCBI chr 7:92,747,671...92,750,886
Ensembl chr 7:106,148,062...106,150,974

G

erythropoietin receptor

CTD Direct Evidence: marker/mechanism

NCBI chr19:10,925,148...10,931,955
Ensembl chr19:11,635,248...11,642,383

G

erb-b2 receptor tyrosine kinase 2

rat gene in a mouse model
CTD Direct Evidence: marker/mechanism

PMID:11238891 PMID:16984552

NCBI chr17:17,560,337...17,600,808
Ensembl chr17:17,777,434...17,805,862

G

erb-b2 receptor tyrosine kinase 3

disease_progression

associated with Prostatic Neoplasms;protein:increased expression, altered localization:bone, nucleus
associated with lung adenocarcinoma
associated with Prostatic Neoplasms;protein:alternative form
CTD Direct Evidence: marker/mechanism

PMID:17634423 PMID:18559590 PMID:26254096 PMID:28114269

RGD:126790470 RGD:2289944 RGD:2298500

NCBI chr12:32,811,533...32,834,958
Ensembl chr12:33,063,434...33,084,994

G

erb-b2 receptor tyrosine kinase 4

disease_progression

associated with lung adenocarcinoma

NCBI chr2B:98,625,630...99,795,371
Ensembl chr2B:217,069,644...218,272,006

G

ERCC excision repair 1, endonuclease non-catalytic subunit

disease_progression

associated with Melanoma
CTD Direct Evidence: marker/mechanism

PMID:20801905 PMID:26202595

NCBI chr19:42,356,039...42,427,754
Ensembl chr19:50,951,674...50,968,430

G

ERCC excision repair 4, endonuclease catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr16:12,848,334...12,880,480
Ensembl chr16:14,272,417...14,304,496

G

endoplasmic reticulum protein 29

CTD Direct Evidence: marker/mechanism

NCBI chr12:109,610,692...109,620,390
Ensembl chr12:113,004,125...113,013,674

G

estrogen receptor 1

CTD Direct Evidence: marker/mechanism

PMID:20104649 PMID:35044086

NCBI chr 6:149,507,599...149,918,523
Ensembl chr 6:154,317,002...154,631,551

G

ETS variant transcription factor 4

CTD Direct Evidence: marker/mechanism

NCBI chr17:13,850,823...13,869,347
Ensembl chr17:14,099,160...14,116,186

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

associated with lung non-small cell carcinoma
associated with stomach cancer;protein:increased expression:stomach
associated with osteosarcoma

PMID:20132185 PMID:24097870 PMID:26265454

RGD:11532507 RGD:126779607 RGD:126781716

NCBI chr 7:140,536,962...140,613,104
Ensembl chr 7:153,017,590...153,059,726

G

ezrin

CTD Direct Evidence: marker/mechanism

NCBI chr 6:156,656,146...156,709,986
Ensembl chr 6:161,670,483...161,723,102

G

coagulation factor II, thrombin

associated with Carcinoma, Small cell;protein:increased expression:brain

NCBI chr11:46,669,925...46,690,391
Ensembl chr11:47,227,891...47,249,157

G

Fas associated via death domain

CTD Direct Evidence: marker/mechanism

NCBI chr11:65,300,889...65,305,020

G

Fas cell surface death receptor

associated with Breast Neoplasms;protein:decreased expression:breast
associated with Mammary Neoplasms;protein:decreased expression:lung

PMID:17352235 PMID:17918178

RGD:2290048 RGD:2290053

NCBI chr10:85,707,457...85,741,539
Ensembl chr10:89,217,949...89,243,612

G

Fas ligand

associated with Breast Neoplasms;protein:decreased expression:breast

NCBI chr 1:148,159,826...148,167,785
Ensembl chr 1:151,868,430...151,876,281

G

fibroblast growth factor 13

CTD Direct Evidence: marker/mechanism

NCBI chr X:127,764,648...128,353,928
Ensembl chr X:138,023,016...138,103,217

G

fibroblast growth factor receptor 1

associated with prostate adenocarcinoma

NCBI chr 8:37,713,133...37,773,098
Ensembl chr 8:34,890,147...34,948,904

G

fms related receptor tyrosine kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:9,584,850...9,779,542

G

fibronectin 1

treatment

associated with stomach cancer; human cells in mouse model

NCBI chr2B:102,623,568...102,698,747
Ensembl chr2B:221,208,431...221,284,003

G

fascin actin-bundling protein 1

associated with Pancreatic Neoplasms

NCBI chr 7:5,848,902...5,862,756

G

ferritin light chain

CTD Direct Evidence: marker/mechanism

NCBI chr19:45,966,431...45,968,015
Ensembl chr19:54,788,854...54,790,465

G

GRB2 associated binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr11:73,275,360...73,478,272
Ensembl chr11:76,896,691...76,967,007

G

growth differentiation factor 15

CTD Direct Evidence: marker/mechanism

NCBI chr19:17,864,840...17,867,883
Ensembl chr19:18,835,216...18,838,470

G

gap junction protein beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:60,490,579...60,492,606
Ensembl chr X:70,547,110...70,547,961

G

glycoprotein Ib platelet subunit alpha

associated with Melanoma, Experimental

NCBI chr17:4,980,083...4,983,219

G

glycerophosphocholine phosphodiesterase 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:5,547,190...5,613,849
Ensembl chr20:5,336,003...5,397,448

G

glucose-6-phosphate isomerase

NCBI chr19:31,301,469...31,355,362
Ensembl chr19:40,024,584...40,080,598

G

glutathione peroxidase 2

CTD Direct Evidence: marker/mechanism

NCBI chr14:45,522,558...45,526,678

G

hyaluronan binding protein 2

treatment

associated with Thyroid Neoplasms

NCBI chr10:110,146,311...110,182,871
Ensembl chr10:113,580,321...113,616,810

G

hepatitis A virus cellular receptor 2

disease_progression

DNA:polymorphisms: : +4259T>G (human)

NCBI chr 5:152,486,125...152,514,004
Ensembl chr 5:159,108,915...159,131,007

G

histone deacetylase 3

associated with Anaphylaxis;
CTD Direct Evidence: marker/mechanism

PMID:24619412 PMID:34973135

NCBI chr 5:136,981,790...136,997,786
Ensembl chr 5:143,094,406...143,110,322

G

hepatocyte growth factor

CTD Direct Evidence: marker/mechanism
associated with Melanoma;
associated with Mammary Neoplasms, Experimental;
associated with Pancreatic Neoplasms

PMID:10688652 PMID:11893931 PMID:16459153 PMID:25971889

RGD:2317904 RGD:8548538 RGD:8548625

NCBI chr 7:73,667,618...73,738,960
Ensembl chr 7:87,327,798...87,397,811

G

heparanase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:40,863,491...40,905,693
Ensembl chr 4:46,709,621...46,755,157

G

histamine receptor H2

CTD Direct Evidence: marker/mechanism

NCBI chr 5:171,004,893...171,057,539
Ensembl chr 5:177,928,039...177,931,566

G

heat shock protein 90 alpha family class A member 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:82,700,881...82,707,020
Ensembl chr14:102,519,699...102,576,723

G

heat shock protein family A (Hsp70) member 1A

CTD Direct Evidence: marker/mechanism

NCBI chr 6:31,476,710...31,491,411

G

integrin binding sialoprotein

CTD Direct Evidence: marker/mechanism

PMID:22407340 PMID:24980816

NCBI chr 4:80,061,960...80,105,560
Ensembl chr 4:90,817,072...90,830,021

G

intercellular adhesion molecule 1

associated with Melanoma, Cutaneous Malignant
associated with Pancreatic Neoplasms;protein:increased expression:serum

PMID:10465581 PMID:12923961

RGD:2325163 RGD:8547593

NCBI chr19:9,821,402...9,837,021
Ensembl chr19:10,484,414...10,500,605

G

inhibitor of DNA binding 1

CTD Direct Evidence: therapeutic

NCBI chr20:27,895,177...27,896,414
Ensembl chr20:28,535,582...28,536,311

G

insulin like growth factor 1

associated with Pancreatic Neoplasms
CTD Direct Evidence: marker/mechanism
associated with Uveal Melanoma;protein:increased expression:serum:

PMID:18398872 PMID:19375852 PMID:23197685

RGD:2317643 RGD:8548834

NCBI chr12:99,986,887...100,066,773
Ensembl chr12:103,385,911...103,462,177

G

insulin like growth factor 1 receptor

associated with Pancreatic Neoplasms

NCBI chr15:77,332,926...77,648,474
Ensembl chr15:96,535,164...96,832,974

G

insulin like growth factor 2

associated with Arthritis, Experimental; protein:increased expression:lung, bone, serum:

NCBI chr11:2,170,190...2,199,442
Ensembl chr11:2,202,743...2,228,890

G

IKAROS family zinc finger 1

associated with colorectal cancer;DNA:polymorphisms:

NCBI chr 7:50,946,817...51,047,168
Ensembl chr 7:51,191,685...51,291,245

G

interleukin 10

NCBI chr 1:182,369,234...182,374,207
Ensembl chr 1:186,648,289...186,653,371

G

interleukin 18

associated with breast cancer;DNA:SNP:promoter:-137G>C (rs187238) (human)
associated with breast cancer;protein:increased expression:serum
CTD Direct Evidence: marker/mechanism

PMID:11215816 PMID:12209760 PMID:12748951 PMID:19152241

RGD:4889862 RGD:8655866 RGD:8655899

NCBI chr11:107,024,376...107,045,194
Ensembl chr11:110,867,586...110,888,371

G

interleukin 2

treatment

associated with melanoma
CTD Direct Evidence: therapeutic
associated with melanoma;
associated with neuroblastoma.

PMID:8610104 PMID:8642346 PMID:9362156 PMID:17105418

RGD:14747043 RGD:14865005 RGD:8663438

NCBI chr 4:114,637,328...114,642,586
Ensembl chr 4:125,782,563...125,787,984

G

interleukin 6

treatment

associated with stomach cancer, human cells in mouse model
CTD Direct Evidence: marker/mechanism

PMID:21937440 PMID:26101800 PMID:28186964

NCBI chr 7:23,415,922...23,420,767

G

integrin subunit alpha 6

NCBI chr2B:59,714,348...59,794,762
Ensembl chr2B:177,169,536...177,250,143

G

integrin subunit beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:33,023,573...33,081,384
Ensembl chr10:33,608,978...33,644,031

G

integrin subunit beta 3

mRNA, protein:increased expression:lung
associated with renal cell carcinoma;DNA:missense mutation:cds:p.L33P (human)

PMID:16831169 PMID:21107114

RGD:5037225 RGD:6907406

NCBI chr17:10,134,450...10,194,596
Ensembl chr17:10,353,111...10,392,382

G

Janus kinase 2

treatment

associated with stomach cancer, human cells in mouse model

NCBI chr 9:4,820,303...4,971,867
Ensembl chr 9:5,006,271...5,156,626

G

junction plakoglobin

associated with Ovarian Neoplasms

NCBI chr17:15,527,115...15,559,251
Ensembl chr17:15,747,163...15,777,479

G

lysine demethylase 6A

disease_progression

associated with lung adenocarcinoma;protein:increased expression:brain (human)

NCBI chr X:37,313,000...37,548,630
Ensembl chr X:45,127,382...45,362,029

G

kinase insert domain receptor

associated with Carcinoma, Renal Cell

NCBI chr 4:68,813,894...68,861,018
Ensembl chr 4:75,377,375...75,427,109

G

kinesin family member 2C

disease_progression

associated with colorectal cancer

NCBI chr 1:44,042,565...44,070,922
Ensembl chr 1:45,408,734...45,436,844

G

KiSS-1 metastasis suppressor

associated with Ovarian Neoplasms

G

lysine methyltransferase 2B

associated with lung adenocarcinoma

NCBI chr19:32,647,815...32,668,656
Ensembl chr19:41,382,458...41,402,695

G

lysine methyltransferase 2D

disease_progression

associated with colorectal cancer;DNA:mutations::

NCBI chr12:39,689,463...39,731,904
Ensembl chr12:40,575,083...40,608,661

G

KRAS proto-oncogene, GTPase

treatment
disease_progression

CTD Direct Evidence: marker/mechanism
associated with stomach cancer; human cells in mouse model
associated with colorectal cancer;DNA:mutation: :
associated with colorectal cancer;DNA:mutations: :
associated with Fibrosarcoma;mRNA,protein:decreased expression::
associated with colorectal cancer; DNA:mutation:cds:

PMID:3552201 PMID:8635384 PMID:26210240 PMID:27264476 PMID:27431311 More...

RGD:11086960 RGD:11570402 RGD:14398745 RGD:14398751 RGD:152995400

NCBI chr12:61,062,689...61,108,524
Ensembl chr12:63,679,293...63,724,335

G

keratin 20

associated with Colorectal Neoplasms

NCBI chr17:16,396,544...16,408,104
Ensembl chr17:16,624,068...16,633,359

G

L1 cell adhesion molecule

treatment

associated with Lung Neoplasms;
associated with Pancreatic Neoplasms;

PMID:22095073 PMID:22307136

RGD:11570404 RGD:11570503

NCBI chr X:143,412,303...143,437,090
Ensembl chr X:153,298,690...153,324,228

G

laminin subunit gamma 2

associated with lung adenocarcinoma;

NCBI chr 1:158,697,084...158,763,209
Ensembl chr 1:162,862,785...162,921,864

G

lipocalin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 9:99,259,278...99,274,494
Ensembl chr 9:127,940,799...127,944,798

G

leukocyte cell derived chemotaxin 2

CTD Direct Evidence: therapeutic

NCBI chr 5:131,338,344...131,347,323
Ensembl chr 5:137,478,111...137,486,448

G

lymphoid enhancer binding factor 1

associated with prostate cancer
CTD Direct Evidence: marker/mechanism

PMID:27067790 PMID:27811057

NCBI chr 4:100,552,959...100,674,156
Ensembl chr 4:111,125,312...111,245,980

G

galectin 3

CTD Direct Evidence: marker/mechanism

NCBI chr14:35,715,850...35,732,263
Ensembl chr14:53,990,023...54,006,412

G

LLGL scribble cell polarity complex component 2

CTD Direct Evidence: marker/mechanism

NCBI chr17:69,474,804...69,524,797
Ensembl chr17:75,025,235...75,075,240

G

keratin, type I cytoskeletal 14

mRNA:decreased expression:epithelial cell

NCBI chr17:15,730,066...15,734,665
Ensembl chr17:15,948,596...15,953,191

G

solute carrier organic anion transporter family member 1B3

associated with Colonic Neoplasms;protein:decreased expression:liver

NCBI chr12:65,386,042...65,492,240

G

calcium release-activated calcium channel protein 1

treatment

associated with stomach cancer; human cells in mouse model

NCBI chr12:119,229,069...119,243,435

G

signal transducer and activator of transcription 5A

disease_progression

DNA:CNV: :prostate (human)

NCBI chr17:15,005,025...15,029,110
Ensembl chr17:15,228,465...15,251,783

G

lymphocyte antigen 96

CTD Direct Evidence: marker/mechanism

NCBI chr 8:70,525,058...70,567,839
Ensembl chr 8:72,169,986...72,207,372

G

MET transcriptional regulator MACC1

treatment

associated with stomach cancer; human cells in mouse model
CTD Direct Evidence: marker/mechanism

PMID:27431311 PMID:36008464

NCBI chr 7:20,826,105...20,904,602
Ensembl chr 7:20,144,960...20,170,423

G

mitogen-activated protein kinase kinase 4

disease_progression

associated with oral squamous cell carcinoma;mRNA, protein:increased expression:lymph node (human)

NCBI chr17:39,497,105...39,622,331
Ensembl chr17:44,248,857...44,359,909

G

mitogen-activated protein kinase 1

treatment

CTD Direct Evidence: marker/mechanism
associated with prostate adenocarcinoma

PMID:22139534 PMID:22580338

NCBI chr22:3,883,119...3,990,368
Ensembl chr22:20,365,487...20,450,335

G

mitogen-activated protein kinase 3

CTD Direct Evidence: marker/mechanism

Ensembl chr16:30,489,362...30,498,017

G

mitogen-activated protein kinase 9

associated with Colorectal Neoplasms
CTD Direct Evidence: therapeutic

PMID:21779479 PMID:25205654

NCBI chr 5:175,437,167...175,495,469
Ensembl chr 5:182,748,381...182,795,135

G

mediator complex subunit 28

CTD Direct Evidence: marker/mechanism

NCBI chr 4:12,035,441...12,051,718
Ensembl chr 4:17,328,975...17,348,546

G

MET proto-oncogene, receptor tyrosine kinase

disease_progression

CTD Direct Evidence: marker/mechanism
associated with Squamous Cell Carcinoma of the Tongue;

PMID:20080979 PMID:21225626 PMID:22704061

NCBI chr 7:108,646,278...108,772,238
Ensembl chr 7:121,365,438...121,468,159

G

marker of proliferation Ki-67

associated with Pancreatic Neoplasms

NCBI chr10:124,684,336...124,714,143
Ensembl chr10:128,936,037...128,962,555

G

mutL homolog 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:36,899,828...36,957,076
Ensembl chr 3:37,189,439...37,245,801

G

matrix metallopeptidase 1

CTD Direct Evidence: marker/mechanism

PMID:12538496 PMID:19487542 PMID:22580338 PMID:23548910

NCBI chr11:97,730,545...97,739,190
Ensembl chr11:101,221,393...101,230,104

G

matrix metallopeptidase 10

CTD Direct Evidence: marker/mechanism

NCBI chr11:97,710,819...97,721,263
Ensembl chr11:101,201,665...101,212,103

G

matrix metallopeptidase 13

associated with Carcinoma, Renal Cell;mRNA, protein:increased expression:bone

NCBI chr11:97,890,811...97,902,778
Ensembl chr11:101,377,001...101,387,679

G

matrix metallopeptidase 2

disease_progression

CTD Direct Evidence: marker/mechanism
associated with pancreatic cancer; protein:increased expression, increased activity:pancreas
associated with Mammary Neoplasms, Animal;protein:increased expression:brain
associated with Gallbladder Neoplasms; protein:increased expression:gallbladder

PMID:12173379 PMID:16158251 PMID:16475674 PMID:18398872 PMID:18665467 More...

RGD:2325743 RGD:2325749 RGD:8547884

NCBI chr16:35,711,866...35,738,881
Ensembl chr16:54,812,694...54,844,279

G

matrix metallopeptidase 24

CTD Direct Evidence: marker/mechanism

NCBI chr20:31,554,770...31,606,348
Ensembl chr20:32,686,887...32,729,403

G

matrix metallopeptidase 3

associated with Mammary Neoplasms, Animal;protein:increased expression:brain

NCBI chr11:97,776,729...97,784,549
Ensembl chr11:101,267,566...101,275,354

G

matrix metallopeptidase 9

severity
disease_progression

associated with skin melanoma;DNA:missense mutation:cds:p.Q279R (human)
CTD Direct Evidence: marker/mechanism
associated with osteosarcoma;protein:increased expression:bone (human)
associated with Melanoma
associated with Mammary Neoplasms, Animal
associated with Mammary Neoplasms, Animal;protein:increased expression:brain
associated with Mammary Neoplasms, Animal; associated with Arthritis, Experimental
associated with pancreatic cancer; protein:increased expression, increased activity:pancreas
associated with carcinoma, pancreatic ductal; protein:increased expression:pancreas

PMID:8912869 PMID:12173379 PMID:15659795 PMID:16033831 PMID:16158251 More...

RGD:152023746 RGD:2325749 RGD:2325855 RGD:5510000 RGD:8547861 RGD:8547878 RGD:8547884 RGD:8547886 RGD:8547928

NCBI chr20:42,346,305...42,354,018
Ensembl chr20:43,432,389...43,440,129

G

mutS homolog 2

associated with Breast Neoplasms

NCBI chr2A:47,524,468...47,602,376
Ensembl chr2A:48,447,207...48,554,461

G

macrophage stimulating 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:49,616,339...49,621,749

G

metadherin

CTD Direct Evidence: therapeutic

NCBI chr 8:94,282,432...94,368,516
Ensembl chr 8:96,473,247...96,551,341

G

methylenetetrahydrofolate reductase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:10,548,196...10,568,174
Ensembl chr 1:11,766,334...11,785,419

G

mechanistic target of rapamycin kinase

associated with Pancreatic Neoplasms

NCBI chr 1:9,871,700...10,028,704
Ensembl chr 1:11,093,765...11,249,841

G

mucin 1, cell surface associated

disease_progression

associated with Carcinoma, Renal Cell;
associated with Pancreatic Neoplasms

PMID:10390012 PMID:12941828 PMID:16707592

RGD:2324648 RGD:2324652 RGD:7245968

NCBI chr 1:130,533,508...130,537,866
Ensembl chr 1:134,141,969...134,145,850

G

mucin 4, cell surface associated

associated with Melanoma

NCBI chr 3:193,050,895...193,114,931

G

mucin 5AC, oligomeric mucus/gel-forming

associated with chloangiocarcinoma;protein:increased expression:bile duct

NCBI chr11:1,191,223...1,234,373

G

mucin 6, oligomeric mucus/gel-forming

disease_progression

associated with cholangiocarcinoma

NCBI chr11:1,035,447...1,071,791
Ensembl chr11:1,077,867...1,106,927

G

MYC proto-oncogene, bHLH transcription factor

CTD Direct Evidence: marker/mechanism

NCBI chr 8:124,387,561...124,393,551
Ensembl chr 8:127,131,512...127,136,863

G

myosin light chain kinase

CTD Direct Evidence: marker/mechanism

PMID:12970723 PMID:18710790

NCBI chr 3:120,711,705...120,983,432
Ensembl chr 3:127,614,173...127,793,261

G

N-acetylglucosamine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr2A:71,114,832...71,125,182
Ensembl chr2A:72,616,077...72,626,435

G

nuclear receptor coactivator 1

CTD Direct Evidence: marker/mechanism

NCBI chr2A:24,485,068...24,764,135
Ensembl chr2A:24,733,117...24,859,488

G

NDC80 kinetochore complex component

disease_progression

associated with melanoma

NCBI chr18:11,666,099...11,711,456
Ensembl chr18:13,972,637...14,018,261

G

N-myc downstream regulated 1

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:15867226 PMID:22972152

NCBI chr 8:129,891,918...129,952,489
Ensembl chr 8:132,866,245...132,926,514

G

nectin cell adhesion molecule 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:41,794,037...41,837,047
Ensembl chr19:50,399,668...50,443,024

G

NFE2 like bZIP transcription factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr2B:64,509,446...64,544,600
Ensembl chr2B:182,214,116...182,248,085

G

nuclear factor kappa B subunit 1

associated with prostate cancer

NCBI chr 4:94,925,048...95,040,849
Ensembl chr 4:105,589,062...105,704,098

G

NFKB inhibitor alpha

associated with prostate cancer;protein:increased serine phosphorylation

NCBI chr14:16,155,331...16,158,588

G

NME/NM23 nucleoside diphosphate kinase 1

CTD Direct Evidence: marker/mechanism
associated with Ovarian Neoplasms

PMID:7622307 PMID:15928304

NCBI chr17:45,243,588...45,252,135
Ensembl chr17:50,113,622...50,131,636

G

NME/NM23 nucleoside diphosphate kinase 2

resistance

NCBI chr17:45,255,982...45,261,541

G

nitric oxide synthase 2

disease_progression

associated with Carcinoma, Pancreatic Ductal
associated with Gallbladder Neoplasms: protein:increased expression:gallbladder
associated with Carcinoma, Pancreatic Ductal; protein:increased expression:pancreas

PMID:12660813 PMID:14991947 PMID:15222037

RGD:2325242 RGD:2325250 RGD:2325254

NCBI chr17:28,984,295...29,021,516
Ensembl chr17:29,471,510...29,617,093

G

nitric oxide synthase 3

susceptibility

protein:increased expression:blood vessel endothelial cell
associated with Prostatic Neoplasms;DNA:polymorphism
associated with Breast Neoplasms;DNA:polymorphism:promoter:-786T>C (human)

PMID:12445681 PMID:14623178 PMID:14672505

RGD:2292080 RGD:2292081 RGD:2292087

NCBI chr 7:142,577,334...142,600,702
Ensembl chr 7:154,730,009...154,755,233

G

natriuretic peptide A

CTD Direct Evidence: therapeutic

NCBI chr 1:10,608,025...10,610,287
Ensembl chr 1:11,825,072...11,827,373

G

NOP2/Sun RNA methyltransferase 6

CTD Direct Evidence: marker/mechanism

NCBI chr10:18,864,484...18,978,297
Ensembl chr10:19,199,642...19,304,089

G

osteoglycin

CTD Direct Evidence: marker/mechanism

NCBI chr 9:63,505,165...63,527,761
Ensembl chr 9:91,578,833...91,600,738

G

oligodendrocyte transcription factor 2

associated with breast cancer

NCBI chr21:19,387,860...19,391,291

G

oncostatin M

CTD Direct Evidence: marker/mechanism

NCBI chr22:11,298,965...11,303,009
Ensembl chr22:29,101,085...29,105,081

G

proliferating cell nuclear antigen

associated with Seminoma

NCBI chr20:5,134,930...5,146,603
Ensembl chr20:4,927,731...4,939,440

G

phosphodiesterase 5A

CTD Direct Evidence: marker/mechanism

NCBI chr 4:111,682,772...111,817,234
Ensembl chr 4:122,832,175...122,966,636

G

platelet derived growth factor subunit B

associated with Breast Neoplasms;mRNA, protein:increased expression:breast

NCBI chr22:20,127,223...20,148,407
Ensembl chr22:37,944,018...37,964,883

G

platelet derived growth factor receptor beta

mRNA,protein:increased expression: :
associated with Carcinoma, Renal Cell

PMID:14593398 PMID:15994946

RGD:13703041 RGD:2292198

NCBI chr 5:145,538,330...145,580,312
Ensembl chr 5:151,543,891...151,585,530

G

phosphatidylethanolamine binding protein 1

associated with Prostatic Neoplasms;protein:decreased expression:

NCBI chr12:115,716,953...115,726,412
Ensembl chr12:119,093,952...119,105,054

G

phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta

CTD Direct Evidence: marker/mechanism

NCBI chr 1:180,024,889...180,096,287
Ensembl chr 1:184,313,233...184,384,454

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

treatment

CTD Direct Evidence: marker/mechanism
associated with colorectal cancer;DNA:mutations::

PMID:23302486 PMID:29106415

NCBI chr 3:176,182,765...176,272,024
Ensembl chr 3:184,355,785...184,441,977

G

phosphoinositide-3-kinase regulatory subunit 3

associated with Adenocarcinoma, Colon

NCBI chr 1:45,345,946...45,481,031
Ensembl chr 1:46,700,153...46,792,920

G

plasminogen activator, urokinase

CTD Direct Evidence: marker/mechanism

NCBI chr10:70,433,340...70,441,569
Ensembl chr10:73,105,895...73,113,136

G

plasminogen activator, urokinase receptor

CTD Direct Evidence: marker/mechanism

NCBI chr19:40,588,100...40,616,479
Ensembl chr19:49,197,341...49,222,561
Ensembl chr19:49,197,341...49,222,561

G

procollagen-lysine,2-oxoglutarate 5-dioxygenase 2

ameliorates

associated with lung non-small cell carcinoma

NCBI chr 3:143,091,833...143,181,831
Ensembl chr 3:150,675,424...150,764,939

G

PML nuclear body scaffold

CTD Direct Evidence: marker/mechanism

NCBI chr15:52,903,874...52,955,151
Ensembl chr15:71,658,884...71,710,883

G

PMS1 homolog 2, mismatch repair system component

CTD Direct Evidence: marker/mechanism

NCBI chr 7:7,433,031...7,459,560
Ensembl chr 7:6,167,403...6,202,984

G

peptidylprolyl isomerase A

CTD Direct Evidence: marker/mechanism

NCBI chr 7:45,510,450...45,515,448
Ensembl chr 7:45,578,765...45,605,545

G

prion protein (Kanno blood group)

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,713,616...4,728,847
Ensembl chr20:4,523,155...4,523,916

G

prospero homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:189,556,124...189,609,297
Ensembl chr 1:194,412,980...194,460,763

G